<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2804257302
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2025
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Itranox
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ITRACONAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Oral solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        484.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="M/s Annora Pharma Private Limited" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            M/s Annora Pharma Private Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Itranox is one of a group of medicines called &ldquo;antifungals&rdquo;. These medicines are used to treat and stop you from getting infections caused by fungi including yeasts.<br />You may be given Itranox to:<br />&bull; treat yeast infections of the mouth, throat or gullet if you have a poor immune system<br />&bull; stop you from getting certain fungal infections if you have a poor immune system due to a major blood disorder or bone marrow transplantation</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Itranox oral solution if you are:<br />&bull; allergic (hypersensitive) to any of the ingredients in Itranox oral solution (listed in Section 6 Contents of the pack and other information</p><p>pregnant, think you might be pregnant or could become pregnant (see the section on Pregnancy) Tell your doctor if you are taking any medicines, before you use Itranox oral solution.<br />&bull; Do not use Itranox oral solution if you are taking any of the following medicines, or within 2 weeks of stopping Itranox oral solution:<br />Medicines to treat problems with the heart, blood or circulation<br />&minus; aliskiren, eplerenone, lercanidipine or nisoldipine (for high blood pressure)<br />&minus; bepridil, ivabradine or ranolazine &ndash; (for angina)<br />&minus; dabigatran or ticagrelor (for blood clots)<br />&minus; disopyramide, dofetilide, dronedarone or quinidine (for irregular heart beat rhythms)<br />&minus; lomitapide, lovastatin or simvastatin (to lower cholesterol)<br />&minus; sildenafil (for pulmonary arterial hypertension)<br />Medicines to treat stomach problems or constipation<br />&minus; cisapride (for stomach upsets)<br />&minus; domperidone (for nausea and vomiting)<br />&minus; naloxegol (for constipation caused by taking opioid painkillers)<br />Medicines to treat headaches, sleep or mental health problems<br />&minus; dihydroergotamine or ergotamine (ergot alkaloids used for migraine headaches)<br />&minus; midazolam (taken by mouth) or triazolam (for sedation or to help you sleep)<br />&minus; lurasidone, pimozide, quetiapine or sertindole (for schizophrenia, bipolar disorder or other mental health problems)<br />Medicines to treat urinary problems<br />&minus; darifenacin (for urinary incontinence)<br />&minus; fesoterodine or solifenacin (for irritated urinary bladder) when used in patients with certain kidney or liver problems<br />Medicines to treat allergies<br />&minus; astemizole, mizolastine or terfenadine (for allergies)<br />Medicines to treat erection and ejaculation problems<br />&minus; avanafil (for erectile dysfunction)<br />&minus; dapoxetine (for premature ejaculation)</p><p>&minus; vardenafil (for erectile dysfunction) when used in men older than 75 years of age<br />Other medicines containing:<br />&minus; colchicine (for gout) when used in patients with kidney or liver problems<br />&minus; ergometrine (ergonovine) or methylergometrine (methylergonovine) ergot alkaloids used after giving birth<br />&minus; eliglustat (for Gaucher&rsquo;s disease) when used in patients that cannot break down certain<br />medicines in the body<br />&minus; halofantrine (for malaria)<br />&minus; irinotecan (for cancer)<br />&minus; isavuconazole (for fungal infections)<br />&minus; ombitasvir, paritaprevir, ritonavir with or without dasabuvir &ndash; (to treat hepatitis C)<br />Remember &ndash; do not take any of the medicines above for 2 weeks after your last treatment with Itranox oral solution.<br />Warnings and precautions<br />Stop taking Itranox and see your doctor immediately if any of the following symptoms of severe liver problems appear during your course of treatment:<br />&bull; Severe lack of appetite, feeling sick, being sick, unusual tiredness, abdominal (stomach) pain, unusually dark urine or pale stools.<br />Tell your doctor immediately:<br />&bull; If you have any unusual feelings of tingling, numbness or weakness in your hands or feet whilst taking Itranox.<br />&bull; If you experience any hearing loss symptoms. In very rare cases patients taking Itranox have reported temporary or permanent hearing loss.<br />Tell your doctor if you have:<br />&bull; had an allergic reaction to any other antifungal medicines<br />&bull; a heart problem, including heart failure (also called congestive heart failure or CHF),<br />Itranox could make it worse. If your doctor decides to give you Itranox, you should be told about the symptoms listed below to watch out for. If you get any of the following stop taking Itranox and tell your doctor straight away. These may be signs of heart failure:</p><p>- shortness of breath<br />- unexpected weight gain<br />- swelling of your legs or stomach<br />- feel unusually tired<br />- wake up short of breath at night<br />&bull; a liver problem, such as jaundice (yellowing of the skin) as your dose of Itranox may have to be changed. Your doctor should give you instructions on symptoms to watch out for. If you have to take Itranox continuously for more than one month, your doctor may want to check your liver by doing blood tests. In addition, there may be specific medication you may not be able to take.<br />&bull; a kidney disorder as your dose of Itranox may have to be changed. In addition, there may be specific medication you may not be able to take.<br />&bull; Cystic fibrosis (a genetic disease affecting the lungs, pancreas, liver, kidneys and intestines).<br />Other medicines and Itranox oral solution<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. There are some medicines that you should not take whilst taking Itranox. These are listed above under the heading &ldquo;Do not use Itranox oral solution if you are:&rdquo;<br />Certain medicines are not recommended for use with Itranox oral solution.<br />Your doctor may decide that you should not take some medicines at the same time as, or within 2 weeks of stopping Itranox oral solution.<br />Examples of these medicines are:<br />Medicines to treat problems with the heart, blood or circulation<br />&minus; apixaban, rivaroxaban or vorapaxar (for blood clots)<br />&minus; atorvastatin (to lower cholesterol)<br />&minus; felodipine (for high blood pressure)<br />&minus; riociguat or tadalafil (for pulmonary hypertension)<br />Medicines to treat epilepsy, headaches or mental health problems<br />&minus; phenytoin, carbamazepine or phenobarbital (anti-epileptics)<br />&minus; eletriptan (for migraine headaches)<br />&minus; St. John&rsquo;s Wort (Hypericum perforatum) (a herbal medicine used for mental health problems)</p><p>Medicines to treat urinary problems<br />&minus; tamsulosin (for male urinary incontinence)<br />&minus; tolterodine (for irritated urinary bladder)<br />Medicines to treat cancer<br />&minus; axitinib, bosutinib, cabazitaxel, cabozantinib, ceritinib, cobimetinib, crizotinib, dabrafenib, dasatinib, docetaxel, ibrutinib, lapatinib, nilotinib, olaparib, pazopanib, regorafenib, sunitinib, trabectedin, trastuzumab emtansine, or vinca alkaloids (eg, vinflunine, vinorelbine)<br />Medicines to treat tuberculosis<br />&minus; bedaquiline, isoniazid, rifabutin or rifampicin (for tuberculosis)<br />Medicines to treat human immunodeficiency virus (HIV) or hepatitis<br />&minus; efavirenz or nevirapine (for HIV/AIDS) elbasvir/grazoprevir, simeprevir, tenofovir<br />alafenamide fumarate (TAF), tenofovir disoproxil fumarate (TDF) (for HIV or hepatitis)<br />Medicines used after organ transplant<br />&minus; everolimus, rapamycin (also known as sirolimus), temsirolimus<br />Medicines to treat benign prostatic enlargement<br />&minus; alfuzosin, silodosin<br />Medicines to treat lung problems or allergies<br />&minus; ciclesonide (for inflammation, asthma and allergies)<br />&minus; ebastine (for allergies)<br />&minus; salmeterol (for asthma or chronic obstructive pulmonary disease -COPD)<br />Medicines to treat erection and ejaculation problems<br />&minus; tadalafil or vardenafil (when used in men 75 years of age and younger) (for erectile dysfunction)<br />Other medicines containing:<br />&minus; colchicine (for gout)<br />&minus; fentanyl (for pain)<br />&minus; lumacaftor/ivacaftor (for cystic fibrosis)</p><p>Remember - do not take any of the medicines above for 2 weeks after your last treatment with Itranox oral solution.<br />This is not a complete list, so tell your doctor if you are taking or planning to take any of these\ medicines, or any other medicines.<br />Care needs to be taken when using Itranox oral solution with certain other medicines You may be more likely to get side effects, or the dose of Itranox oral solution or the other medicine might need to be changed. Examples of these medicines are:<br />Medicines to treat problems with the heart, blood or circulation<br />&minus; bosentan (for pulmonary hypertension)<br />&minus; calcium channel blockers such as, dihydropyridines such as amlodipine, isradipine,<br />nifedipine, nimodipine or diltiazem (for hypertension)<br />&minus; or verapamil (for high blood pressure)<br />&minus; cilostazol (for circulatory problems)<br />&minus; &lsquo;coumarins&rsquo; such as warfarin (for blood clots)<br />&minus; digoxin (for atrial fibrillation)<br />&minus; nadolol (for pulmonary hypertension or angina)<br />Medicines to treat stomach problems or diarrhoea<br />&minus; aprepitant or netupitant (for nausea and vomiting during cancer treatment)<br />&minus; loperamide (for diarrhoea)<br />&minus; antacids such as aluminium, calcium, magnesium, or sodium bicarbonate; H2-receptor antagonists such as cimetidine, ranitidine and proton pump inhibitors such as lansoprazole, omeprazole, rabeprazole (to treat stomach acid problems)<br />Medicines to treat sleep problems or mental health problems<br />&minus; Alprazolam, brotizolam, buspirone, or midazolam (when injected into a vein) (for anxiety or<br />to help you sleep)<br />&minus; zopiclone (to help you sleep)<br />&minus; reboxetine or venlafaxine (for depression and anxiety)<br />&minus; aripiprazole, cariprazine, haloperidol or risperidone (for schizophrenia, bipolar disorder or other mental health problems)</p><p>&minus; galantamine (for Alzheimer&rsquo;s disease)<br />&minus; guanfacine (for attention deficit hyperactivity disorder)<br />Medicines to treat urinary problems<br />&minus; imidafenacin, fesoterodine, oxybutynin, solifenacin (for irritated urinary bladder)<br />Medicines to treat cancer<br />&minus; bortezomib, brentuximab vedotin busulfan, erlotinib, gefitinib, idelalisib, imatinib, nintedanib, panobinostat, ponatinib, ruxolitinib or sonidegib<br />Medicines to treat infections<br />&minus; ciprofloxacin, clarithromycin, or erythromycin (for bacterial infections)<br />&minus; delamanid (for tuberculosis)<br />&minus; artemether-lumefantrine or quinine (to treat malaria)<br />&minus; praziquantel (for fluke and tapeworms)<br />Medicines to treat human immunodeficiency virus (HIV) or hepatitis<br />&minus; cobicistat, boosted elvitegravir, maraviroc, ritonavir, ritonavir-boosted darunavir, ritonavir-<br />boosted fosamprenavir, indinavir or saquinavir (for HIV)<br />&minus; glecaprevir/pibrentasvir (for hepatitis)<br />Medicines used after organ transplant<br />&minus; cyclosporine or tacrolimus<br />Medicines to treat benign prostatic enlargement<br />&minus; dutasteride<br />Medicines to treat lung problems, allergies or inflammatory conditions<br />&minus; bilastine or rupatadine (for allergy)<br />&minus; methylprednisolone or dexamethasone, (medicines given by mouth or injection for asthma, allergies or inflammatory conditions)<br />&minus; budesonide or fluticasone (for asthma, allergies)<br />Medicines to treat erection and ejaculation problems<br />&minus; sildenafil (for erectile dysfunction)<br />Medicines to treat pain<br />&minus; alfentanil, buprenorphine, oxycodone or sufentanil (for pain)</p><p>&minus; meloxicam (for joint inflammation and pain)<br />Other medicines containing:<br />&minus; alitretinoin (given by mouth) (for eczema)<br />&minus; cabergoline (for Parkinson&rsquo;s disease)<br />&minus; cannabis based products including medicines (such as for nausea and vomiting or muscle<br />spasms in patients with multiple sclerosis)<br />&minus; cinacalcet (for an over active parathyroid)<br />&minus; dienogest or ulipristal (contraceptives)<br />&minus; eliglustat (for Gaucher&rsquo;s disease) when used in patients that cannot break down certain<br />medicines in the body<br />&minus; ivacaftor; (for cystic fibrosis)<br />&minus; methadone (to treat drug addiction)<br />&minus; repaglinide or saxagliptin (for diabetes)<br />This is not a complete list, so tell your doctor if you are taking or planning to take any of these medicines, or any other medicines.<br />Itranox oral solution with food and drink<br />Do not take Itranox with food or drink as it reduces your body&rsquo;s ability to absorb the medicine. Always take Itranox oral solution one hour before any food or drink as this helps the body absorb the medicine. Children<br />Itranox is not normally given to children. Your doctor may prescribe it in special cases.<br />Itranox contains cyclodextrin, propylene glycol and alcohol (ethanol). Do not use in children less than 2 years old unless recommended by your doctor. If your child is less than 5 years old, talk to your doctor or pharmacist before giving them this medicine, in particular if the child is given other medicines that contain cyclodextrin, propylene glycol or alcohol.<br />Elderly<br />Itranox is not normally given to the elderly. Your doctor may prescribe it in special cases.<br />Pregnancy<br />Do not take Itranox if you are pregnant, unless your doctor has told you to. If you are of child bearing age and could become pregnant, talk to your doctor. You should use effective contraceptives to make</p><p>sure that you do not become pregnant while you are taking your medicine. As Itranox remains in the body for some time after you stop taking it, you should continue to use some form of contraception until your next period after your treatment with Itranox has finished.<br />If you do find that you are pregnant after starting a course of Itranox , stop taking it and tell your doctor straight away.<br />Before taking any medicine - always tell your doctor if you are pregnant, think you might be pregnant or are trying to become pregnant.<br />Breast-feeding<br />If you are breast-feeding do not take Itranox, as small amounts of the medicine could be present in your breast milk. If, your doctor recommends taking Itranox they may carry out extra checks while you are taking this medicine.<br />Driving and using machines<br />Itranox can sometimes cause dizziness, blurred/double vision or hearing loss. If you have these<br />symptoms, do not drive or use machines.<br />Itranox oral solution contains sorbitol<br />This medicine contains 7 920 mg sorbitol in a 40 mL dose which is equivalent to 198 mg in each mL. If your doctor has told you that you (or your child) have an intolerance to some sugars or if you have been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disorder in which a person cannot break down fructose, talk to your doctor before you (or your child) take this medicine. Sorbitol is a source of fructose and may cause gastrointestinal discomfort and mild laxative effect.<br />Itranox oral solution contains propylene glycol<br />This medicine contains 4.2 g of propylene glycol in each 40 mL dose which is equivalent to 104 mg/mL. If you are pregnant, breast-feeding or suffer from a liver or kidney disease, do not take this medicine unless recommended by your doctor. Your doctor may carry out extra checks while you are taking this medicine.<br />Itranox oral solution contains cyclodextrin<br />This medicine contains 16 000 mg cyclodextrin (s) in each 40 mL which is equivalent to 400 mg/mL.<br />Cyclodextrin may cause digestive problems such as diarrhoea.</p><p>Itranox oral solution contains alcohol (ethanol)<br />This medicine contains 0.2 mg of alcohol (ethanol) in each 40 mL dose which is equivalent to 0.005<br />mg/mL. The amount in 40 mL of this medicine is equivalent to less than 1 mL of beer or 1 mL wine.<br />The small amount of alcohol in this medicine will not have any noticeable effects.<br />Itranox oral solution contains sodium<br />This medicine contains less than 1 mmol sodium (23 mg) per 40 mL, that is to say essentially &lsquo;sodium- free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Itranox oral solution one hour before any food or drink as this helps the body absorb the medicine.<br />You should swish the oral solution around in your mouth for approximately 20 seconds before swallowing it. Do not rinse your mouth after swallowing the oral solution.<br />Always take Itranox exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.<br />A measuring cup graduated to indicate 10 mL is provided. Ensure you fill the cup to the 10 mL mark.<br />How to take Itranox oral solution<br />&bull; Treatment of yeast infections of the mouth, throat or gullet<br />The usual dose is 2 measuring cups (20 mL) per day for one week. This may be taken either all at once or in two divided doses during the day.<br />If after one week of using Itranox, your infection has not cleared, your doctor may decide to continue your treatment for one more week.<br />&bull; Treatment of yeast infections of the mouth, throat or gullet, that have already been treated with another antifungal but have still not cleared<br />The usual dose is 1-2 measuring cups (10-20 mL) twice daily for two weeks. The treatment may be continued for an additional two weeks, if the infection does not clear in the initial two weeks of treatment. For patients on the higher dose of 400 mg (4 measuring cups) daily, treatment should be limited to 14 days, if there are no signs of improvement during this time.<br />&bull; Prevention of fungal infections<br />The dose is calculated according to your body weight (5 mg per kg) given in two divided doses. Your doctor will tell you exactly how much you should take.<br />Directions for opening the bottle<br />The bottle comes with a child-proof cap, and should be opened as follows: push the plastic screw cap down, while turning it counter clockwise.<br />How to use the measuring cup<br />Use the measuring cup just as it sits on the bottle. Make sure that the side with the graduations (the side that holds less) is uppermost; that is the side you have to fill. When the arrow on the side points up, the correct side is uppermost.<br />If you take too much Itranox oral solution<br />If you, or anyone else, take more Itranox than you were told to, contact your doctor or local hospital without delay.<br />If you forget to take Itranox oral solution If you forget to take your medicine, take the next dose as usual and continue your medicine as directed by your doctor. Do not take a double dose.<br />If you have any further questions on the use of Itranox, ask your doctor or pharmacist.<br /><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Itranox oral solution can cause side effects, although not everybody gets them. Medicines can cause serious allergic reactions. Stop taking Itranox and contact your doctor immediately if you have:<br />&bull; any sudden wheeziness, difficulty in breathing, swelling of the face, rash, itching (especially affecting the whole body) or a severe skin disorder (widespread rashes with peeling skin and blisters in the mouth, eyes and genitals, or rashes with small pustules or blisters).<br />&bull; severe lack of appetite, feeling sick, being sick, unusual tiredness, abdominal (stomach) pain, unusually dark urine, or pale stools. These may be symptoms of severe liver problems.<br />You should also let your doctor know immediately if you have any of the side effects below:</p><p>&bull; Symptoms that resemble heart failure such as shortness of breath, unexpected weight gain, swelling of the legs, unusual fatigue (tiredness), repeated waking at night.<br />&bull; A tingling sensation, sensitivity to light, numbness or weakness in the limbs.<br />&bull; Blurred vision/double vision, ringing in your ears, lose the ability to control your urine or<br />increased need to urinate (pass water).<br />&bull; If you experience any hearing loss symptoms.<br />&bull; severe upper stomach pain, often with nausea and vomiting due to inflammation of the pancreas (pancreatitis).<br />Other side effects include:<br />Common side effects (occur in less than 1 in 10 patients) are:<br />&bull; headache<br />&bull; stomach ache, feeling sick (nausea), being sick (vomiting), diarrhoea, indigestion, unpleasant taste<br />&bull; rash<br />&bull; fever or high temperature<br />&bull; shortness of breath<br />&bull; dizziness<br />&bull; cough<br />Uncommon side effects (occur in less than 1 in 100 patients) are:<br />&bull; certain blood disorders which may increase the risk of bleeding or bruising (possible symptoms of low levels of platelets), or infections (possible symptom of low levels of white blood cells)<br />&bull; constipation<br />&bull; itching, hives<br />&bull; general swelling<br />&bull; muscle cramps or irregular heart beat (possible symptoms of low blood levels of potassium)<br />&bull; muscle pain, painful joints<br />&bull; abnormal menstrual bleeding<br />&bull; decreased feeling or sensitivity, especially in the skin<br />The following side effects have been reported in patients taking Itranox with unknown frequency:<br />&bull; excess of triglycerides (fats) in the blood<br />&bull; hair loss<br />&bull; increase in blood creatine phosphokinase levels</p><p>The following side effects have been reported in patients taking other formulations of Itranox:<br />&bull; infection of the upper respiratory tract<br />&bull; inflammation of the nose<br />&bull; inflammation of the sinuses<br />&bull; certain blood disorder which may increase the risk of infections (possible symptom of low levels of granulocytes)<br />&bull; high blood sugar levels<br />&bull; muscle cramps or irregular heart beat (possible symptoms of low blood levels of magnesium)<br />&bull; muscle cramps or irregular heart beat (possible symptoms of high blood levels of potassium)<br />&bull; confusion<br />&bull; sleepiness<br />&bull; tremors<br />&bull; increase in heart rate<br />&bull; high blood pressure<br />&bull; low blood pressure<br />&bull; fluid in the lungs<br />&bull; difficulty speaking<br />&bull; excess gas in the intestinal tract<br />&bull; increases in specific liver function tests (hepatic enzyme increased)<br />&bull; inflammation of the liver (hepatitis)<br />&bull; yellowing of the skin (jaundice)<br />&bull; excess sweating<br />&bull; kidney problems<br />&bull; excessive urine production<br />&bull; erectile dysfunction<br />&bull; general swelling<br />&bull; facial swelling<br />&bull; chest pain<br />&bull; pain<br />&bull; chills<br />&bull; fatigue</p><p>increase in blood urea levels<br />&bull; abnormal urine findings<br />Reporting of side effects<br />If any of side effects gets serious, or if you notice any side effect not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Store below 30&deg;C.<br />&bull; Keep out of reach of children.<br />&bull; Do not use this medicine after the expiry date which is stated on the pack after EXP. The expiry date refers to the last day of the month.<br />&bull; This medicine does not require any special storage conditions.<br />&bull; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how<br />to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Itranox contains<br />The active substance is ltraconazole.<br />&bull; Each ml contains 10mg of ltraconazole in an aqueous solution<br />The other ingredients are: Hydroxypropyl betadex (Kleptose HPB), Propylene glycol, Hydrochloric acid 37%, Non-crystallizing sorbitol solution 70% (SORBIDEX 71205), Saccharin sodium, ART Cherry flavor # 349, ART Cherry flavor # 842, Ascorbic acid and Sodium hydroxide (pellets, extra- pure).<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Itranox looks like?
Clear, colorless to yellowish brown liquid having cherry flavor filled in Amber glass (type Ill) bottle.
How supplied:
Itranox is Supplied in Glass Bottle Pack (150mL).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder Saudi Amarox Industrial Company<br />Al Jamiah Street, Al Malaz District Riyadh 12629, Saudi Arabia<br />Tel &amp; Fax: +966 11 226 8850<br />Manufacturer<br />Annora Pharma Limited , India.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in October 2023, Version 1.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">إترانوكس هي إحدى مجموعات الأدوية المسماة &quot;مضادات الفطريات&quot;. تستخدم هذه الأدوية في علاجك ومنعك من الإصابة بالعدوى التي تسببها الفطريات بما في ذلك الخمائر.</p><p dir="RTL">قد يتم إعطاؤك إترانوكس في الحالات التالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج عدوى فطرية في الفم أو الحلق أو المريء إذا كنت تعاني من ضعف في جهاز المناعة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; منعك من الإصابة بعدوى فطرية معينة إذا كان لديك جهاز مناعي ضعيف بسبب اضطراب كبير في الدم أو زرع نخاع العظم</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم إترانوكس محلول فموي إذا كنت</strong><strong>:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من حساسية (شديدة الحساسية) لأي من مكونات محلول إترانوكس الفموي (المدرجة في القسم 6 محتويات العبوة ومعلومات أخرى)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حامل، تعتقدين أنك حامل أو يمكن أن تصبحي حاملاً (انظر القسم الخاص بالحمل)</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أي أدوية قبل أن تستخدم محلول إترانوكس عن طريق الفم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم إترانوكس محلول فموي إذا كنت تتناول أيًا من الأدوية التالية، أو خلال أسبوعين من إيقاف محلول إترانوكس عن طريق الفم:</p><p dir="RTL"><strong>أدوية لعلاج مشاكل القلب أو الدم أو الدورة الدموية</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أليسكيرين، أبليرينون، ليركانديبين أو نيسولديبين (لارتفاع ضغط الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بيبريديل، إيفابرادين أو رانولازين - (لعلاج الذبحة الصدرية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دابيجاتران أو تيكاجريلور (لتجلط الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديسوبيراميد، دوفيتيليد، درونيدارون أو كينيدين (لعدم انتظام ضربات القلب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لوميتابيد، لوفاستاتين أو سيمفاستاتين (لخفض الكوليسترول)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلدينافيل (لعلاج ارتفاع ضغط الدم الشرياني الرئوي).</p><p dir="RTL"><strong>أدوية لعلاج مشاكل المعدة أو الإمساك</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيسابريد (لاضطرابات المعدة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دومبيريدون (لعلاج الغثيان والقيء).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نالوكسيغول (للإمساك الناجم عن تناول المسكنات الأفيونية)</p><p dir="RTL"><strong>أدوية لعلاج الصداع والنوم أو مشاكل الصحة العقلية</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثنائي هيدروإرجوتامين أو إرجوتامين (قلويدات الإرجوت المستخدمة في الصداع النصفي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميدازولام (يؤخذ عن طريق الفم) أو تريازولام (للتهدئة أو لمساعدتك على النوم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لوراسيدون، بيموزيد، كيتيابين أو سرتيندول (لمرض انفصام الشخصية، اضطراب ثنائي القطب أو مشاكل الصحة العقلية الأخرى)</p><p dir="RTL"><strong>أدوية لعلاج مشاكل المسالك البولية</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داريفيناسين (لعلاج سلس البول)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيزوتيرودين أو سوليفيناسين (لتهيج المثانة البولية) عند استخدامه في المرضى الذين يعانون من مشاكل معينة في الكلى أو الكبد.</p><p dir="RTL"><strong>أدوية لعلاج الحساسية</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أستيميزول، ميزولاستين أو تيرفينادين (للحساسية).</p><p dir="RTL"><strong>أدوية لعلاج مشاكل الانتصاب والقذف</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; افانافيل (لعلاج ضعف الانتصاب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دابوكستين (لسرعة القذف)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فاردينافيل (لعلاج ضعف الانتصاب) عند استخدامه للرجال الذين تزيد أعمارهم عن 75 عامًا</p><p dir="RTL"><strong>أدوية أخرى تحتوي على</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كولشيسين (للنقرس) عند استخدامه في المرضى الذين يعانون من مشاكل في الكلى أو الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إرجومترين (إرجونوفين) أو ميثيل ارجومترين قلويدات الإرجوت المستخدمة بعد الولادة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيليجلوستات (لمرض جوشر) عند استخدامه في المرضى الذين لا يستطيعون تحمل بعض الأدوية في الجسم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هالوفانترين (للملاريا)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيرينوتيكان (للسرطان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ايزافوكونازول (لعلاج الالتهابات الفطرية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أومبيتاسفير، باريتابريفير، ريتونافير مع أو بدون داسابوفير - (لعلاج التهاب الكبد سي)</p><p dir="RTL">تذكر - لا تتناول أي من الأدوية المذكورة أعلاه لمدة أسبوعين بعد آخر علاج لك بمحلول إترانوكس عن طريق الفم.</p><p dir="RTL"><strong>ا</strong><strong>لتحذيرات والاحتياطات</strong></p><p dir="RTL">توقف عن تناول إترانوكس واستشر طبيبك على الفور في حالة ظهور أي من الأعراض التالية لمشاكل الكبد الشديدة أثناء العلاج:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص حاد في الشهية، والشعور بالغثيان، والمرض، والتعب غير المعتاد، وآلام البطن (المعدة)، والبول الداكن بشكل غير عادي، أو البراز الشاحب.</p><p dir="RTL"><strong>أخبر طبيبك على الفور</strong><strong>:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أي شعور غير عادي بالوخز أو التنميل أو الضعف في يديك أو قدميك أثناء تناول إترانوكس.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أي من أعراض فقدان السمع. في حالات نادرة جدًا، أبلغ المرضى الذين يتناولون إترانوكس عن ضعف مؤقت أو دائم في السمع.</p><p dir="RTL">أخبر طبيبك إذا كان لديك:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي تجاه أي أدوية أخرى مضادة للفطريات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلة في القلب، بما في ذلك قصور القلب (وتسمى أيضًا قصور القلب الاحتقاني أو قصور القلب الاحتقاني)،</p><p dir="RTL">&nbsp;إترانوكس يمكن أن يجعل الأمر أسوأ. إذا قرر طبيبك إعطائك إترانوكس، فيجب إخبارك بالأعراض المذكورة أدناه لتنتبه لها. إذا حصلت على أي مما يلي، توقف عن تناول إترانوكس وأخبر طبيبك على الفور. قد تكون هذه علامات على قصور القلب:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة غير متوقعة في الوزن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ في ساقيك أو معدتك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشعر بتعب غير عادي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استيقظ ليلاً بسبب ضيق في التنفس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلة في الكبد، مثل اليرقان (اصفرار الجلد) حيث قد يلزم تغيير جرعتك من إترانوكس. يجب أن يعطيك طبيبك تعليمات حول الأعراض التي يجب الانتباه إليها. إذا اضطررت إلى تناول إترانوكس بشكل مستمر لأكثر من شهر، فقد يرغب طبيبك في فحص الكبد عن طريق إجراء فحوصات الدم. بالإضافة إلى ذلك، قد يكون هناك دواء محدد قد لا تتمكن من تناوله.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب في الكلى حيث قد يلزم تغيير جرعتك من إترانوكس. بالإضافة إلى ذلك، قد يكون هناك دواء محدد قد لا تتمكن من تناوله.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التليف الكيسي (مرض وراثي يصيب الرئتين والبنكرياس والكبد والكلى والأمعاء).</p><p dir="RTL"><strong>تناول الأدوية الأخرى ومحلول إترانوكس عن طريق الفم</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى. هناك بعض الأدوية التي لا يجب عليك تناولها أثناء تناول إترانوكس. هذه مذكورة أعلاه تحت عنوان &quot;لا تستخدم إترانوكس محلول فموي إذا كنت:&quot;</p><p dir="RTL">لا ينصح باستخدام بعض الأدوية مع محلول إترانوكس عن طريق الفم.</p><p dir="RTL">قد يقرر طبيبك أنه لا ينبغي عليك تناول بعض الأدوية في نفس الوقت أو في غضون أسبوعين من التوقف عن تناول محلول إترانوكس عن طريق الفم.</p><p dir="RTL">ومن أمثلة هذه الأدوية:</p><p dir="RTL"><strong>&nbsp;</strong><strong>أدوية لعلاج مشاكل القلب أو الدم أو الدورة الدموية</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أبيكسابان، ريفاروكسابان أو فوراباكسار (لتجلط الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أتورفاستاتين (لخفض الكوليسترول)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيلوديبين (لارتفاع ضغط الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريوسيجوات أو تادالافيل (لارتفاع ضغط الدم الرئوي)</p><p dir="RTL"><strong>أدوية لعلاج الصرع أو الصداع أو مشاكل الصحة العقلية</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفينيتوين أو كاربامازيبين أو فينوباربيتال (مضادات الصرع)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إليتريبتان (لعلاج الصداع النصفي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جون (العرن المثقوب) (دواء عشبي يستخدم لمشاكل الصحة العقلية)</p><p dir="RTL"><strong>أدوية لعلاج مشاكل المسالك البولية</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تامسولوسين (لعلاج سلس البول عند الذكور)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تولتيرودين (لتهيج المثانة البولية).</p><p dir="RTL"><strong>أدوية لعلاج السرطان</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أكسيتينيب، بوسوتينيب، كابازيتاكسيل، كابوزانتينيب، سيريتينيب، كوبيميتينيب، كريزوتينيب، دابرافينيب، داساتينيب، دوسيتاكسيل، إيبروتينيب، لاباتينيب، نيلوتينيب، أولاباريب، بازوبانيب، ريجورافينيب، أو فينايتينيب،</p><p dir="RTL"><strong>أدوية لعلاج السل</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بيداكويلين، أيزونيازيد، ريفابوتين أو ريفامبيسين (لمرض السل)</p><p dir="RTL"><strong>أدوية لعلاج فيروس نقص المناعة البشرية</strong><strong> </strong><strong>(</strong><strong>HIV</strong><strong>) أو التهاب الكبد</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيفافيرينز أو نيفيرابين (لفيروس نقص المناعة البشرية / الإيدز) الباسفير / جرازوبريفير، سيميبريفير، تينوفوفير ألافيناميدي فومارات (TAF)، تينوفوفير ديسوبروكسيل فومارات (TDF) (لفيروس نقص المناعة البشرية أو التهاب الكبد)</p><p dir="RTL"><strong>الأدوية المستخدمة بعد زراعة الأعضاء</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيفروليموس، رابامايسين (المعروف أيضًا باسم سيروليموس)، تيمسيروليموس</p><p dir="RTL"><strong>أدوية لعلاج تضخم البروستاتا الحميد</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفوزوسين، سيلودوسين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج مشاكل الرئة أو الحساسية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكليسونيد (للالتهابات والربو والحساسية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ايباستين (للحساسية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سالميتيرول (لعلاج الربو أو مرض الانسداد الرئوي المزمن - COPD)</p><p dir="RTL"><strong>أدوية لعلاج مشاكل الانتصاب والقذف</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تادالافيل أو فاردينافيل (عند استخدامه للرجال بعمر 75 عامًا أو أقل) (لعلاج ضعف الانتصاب)</p><p dir="RTL"><strong>أدوية أخرى تحتوي على</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كولشيسين (للنقرس)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينتانيل (للألم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لوماكافتور / ايفاكافتور (للتليف الكيسي)</p><p dir="RTL"><strong>تذكر - لا تتناول أي من الأدوية المذكورة أعلاه لمدة أسبوعين بعد آخر علاج لك باستخدام </strong><strong>إترانوكس محلول عن طريق الفم</strong><strong>.</strong></p><p dir="RTL">هذه ليست قائمة كاملة، لذا أخبر طبيبك إذا كنت تتناول أو تخطط لأخذ أي منها.</p><p dir="RTL"><strong>تناول إترانوكس ، أو أي أدوية أخرى</strong><strong>.</strong></p><p dir="RTL">يجب توخي الحذر عند استخدام محلول إترانوكس عن طريق الفم مع بعض الأدوية الأخرى</p><p dir="RTL">قد تكون أكثر عرضة للإصابة بأعراض جانبية، أو جرعة إترانوكس عن طريق الفم أو غيرها</p><p dir="RTL">قد يحتاج الدواء إلى التغيير. ومن أمثلة هذه الأدوية:</p><p dir="RTL"><strong>&nbsp;</strong><strong>أدوية لعلاج مشاكل القلب أو الدم أو الدورة الدموية</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بوسنتان (لعلاج ارتفاع ضغط الدم الرئوي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاصرات قنوات الكالسيوم مثل ديهيدروبيريدين مثل أملوديبين، إيزراديبين، نيفيديبين، نيموديبين أو ديلتيازيم (لارتفاع ضغط الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو فيراباميل (لارتفاع ضغط الدم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلوستازول (لمشاكل الدورة الدموية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &quot;الكومارين&quot; مثل الوارفارين (لتجلط الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الديجوكسين (للرجفان الأذيني)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نادولول (لارتفاع ضغط الدم الرئوي أو الذبحة الصدرية)</p><p dir="RTL"><strong>أدوية لعلاج مشاكل المعدة أو الإسهال</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أبريبتانت أو نيتوبيتانت (للغثيان والقيء أثناء علاج السرطان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لوبيراميد (للإسهال).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الحموضة مثل الألومنيوم والكالسيوم والمغنيسيوم وبيكربونات الصوديوم؛ مضادات مستقبلات H2 مثل السيميتيدين، الرانيتيدين ومثبطات مضخة البروتون مثل لانزوبرازول، أوميبرازول، رابيبرازول (لعلاج مشاكل حمض المعدة)</p><p dir="RTL"><strong>أدوية لعلاج مشاكل النوم أو مشاكل الصحة العقلية</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألبرازولام، بروتيزولام، بوسبيرون، أو ميدازولام (عند حقنه في الوريد ((للقلق أو لمساعدتك على النوم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زوبيكلون (لمساعدتك على النوم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريبوكستين أو فينلافاكسين (لعلاج الاكتئاب والقلق).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أريبيبرازول، كاريبرازين، هالوبيريدول أو ريسبيريدون (لمرض انفصام الشخصية، اضطراب ثنائي القطب أو مشاكل الصحة العقلية الأخرى)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جالانتامين (لمرض الزهايمر)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جوانفاسين (لعلاج اضطراب فرط الحركة ونقص الانتباه)</p><p dir="RTL"><strong>أدوية لعلاج مشاكل المسالك البولية</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيميدافيناسين، فيزوتيرودين، أوكسيبوتينين، سوليفيناسين (للمثانة البولية المتهيجة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج السرطان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بورتيزوميب، برنتوكسيماب فيدوتين بوسولفان، إرلوتينيب، جيفيتينيب، إدياليسيب، إيماتينيب، نينتيدانيب، بانوبينوستات، بوناتينيب، روكسوليتينيب أو سونيدجيب</p><p dir="RTL"><strong>أدوية لعلاج الالتهابات</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيبروفلوكساسين أو كلاريثروميسين أو إريثروميسين (للالتهابات البكتيرية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دلامانيد (لمرض السل)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أرتيميثير - لوميفانترين أو كينين (لعلاج الملاريا)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; برازيكوانتيل (لديدان فلوك والديدان الشريطية)</p><p dir="RTL"><strong>أدوية لعلاج فيروس نقص المناعة البشرية</strong><strong> </strong><strong>(</strong><strong>HIV</strong><strong>) أو التهاب الكبد</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كوبيسيستات، إلفيتيجرافير، مارافيروك، ريتونافير، دارونافير بالريتونافير، ريتونافير، فوسامبرينافير، إندينافير أو ساكوينافير (لفيروس نقص المناعة البشرية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جليكابريفير / بيبرنتاسفير (لالتهاب الكبد)</p><p dir="RTL"><strong>الأدوية المستخدمة بعد زراعة الأعضاء</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين أو تاكروليموس</p><p dir="RTL"><strong>أدوية لعلاج تضخم البروستاتا الحميد</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوتاستيريد</p><p dir="RTL"><strong>أدوية لعلاج مشاكل الرئة أو الحساسية أو الأمراض الالتهابية</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بلاستين أو روباتادين (للحساسية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثيل بريدنيزولون أو ديكساميثازون (الأدوية التي تُعطى عن طريق الفم أو الحقن للربو أو الحساسية أو الحالات الالتهابية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بوديزونيد أو فلوتيكاسون (لعلاج الربو والحساسية).</p><p dir="RTL"><strong>أدوية لعلاج مشاكل الانتصاب والقذف</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلدينافيل (لعلاج ضعف الانتصاب)</p><p dir="RTL"><strong>أدوية لعلاج الآلام</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفنتانيل، البوبرينورفين، أوكسيكودون أو سوفنتانيل (للألم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميلوكسيكام (لالتهاب المفاصل وآلامها).</p><p dir="RTL"><strong>أدوية أخرى تحتوي على</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أليتريتينوين (عن طريق الفم) (للإكزيما).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كابيرجولين (لمرض باركنسون)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المنتجات التي تحتوي على القنب بما في ذلك الأدوية (مثل الغثيان والقيء أو التشنجات العضلية لدى مرضى التصلب المتعدد)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيناكالسيت (لعلاج فرط نشاط الغدة الجار درقية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دينوجيست أو يوليبريستال (موانع الحمل)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيليجلوستات (لمرض جوشر) عند استخدامه في المرضى الذين لا يستطيعون تحمل بعض الأدوية في الجسم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيفاكافتور (لعلاج التليف الكيسي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الميثادون (لعلاج إدمان المخدرات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريباجلينيد أو ساكساجليبتين (لمرض السكري)</p><p dir="RTL">هذه ليست قائمة كاملة، لذا أخبر طبيبك إذا كنت تتناول أو تخطط لتناول أي من هذه الأدوية، أو أي أدوية أخرى.</p><p dir="RTL"><strong>إترانوكس محلول عن طريق الفم مع الطعام والشراب</strong></p><p dir="RTL">لا تتناول إترانوكس مع الطعام أو الشراب لأنه يقلل من قدرة جسمك على امتصاص الدواء. يجب تناول إترانوكس دائمًا قبل تناول أي طعام أو شراب بساعة واحدة لأن ذلك يساعد الجسم على امتصاص الدواء.</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">إترانوكس لا يعطى للأطفال عادة. قد يصفه طبيبك في حالات خاصة.</p><p dir="RTL">يحتوي إترانوكس على سيكلودكسترين وبروبيلين جليكول وكحول (إيثانول). لا تستخدم في الأطفال أقل من عامين إلا إذا أوصى طبيبك. إذا كان عمر طفلك أقل من 5 سنوات، تحدث إلى طبيبك أو الصيدلي قبل إعطائهم هذا الدواء، لا سيما إذا تم إعطاء الطفل أدوية أخرى تحتوي على سيكلودكسترين أو بروبيلين جليكول أو كحول.</p><p dir="RTL"><strong>كبار السن</strong></p><p dir="RTL">لا يتم إعطاء إترانوكس عادة للمسنين. قد يصفه طبيبك في حالات خاصة.</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">يجب عدم استخدام إترانوكس إذا كنت حاملاً، إلا إذا أخبرك طبيبك بذلك. إذا كنت في سن الإنجاب ويمكن أن تصبحين حاملاً، تحدثي إلى طبيبك. يجب عليك استخدام وسائل منع الحمل الفعالة</p><p dir="RTL">تأكدي من عدم الحمل أثناء تناول دوائك. نظرًا لأن إترانوكس يظل في الجسم لبعض الوقت بعد التوقف عن تناوله، فيجب عليك الاستمرار في استخدام بعض وسائل منع الحمل حتى دورتك الشهرية التالية بعد انتهاء العلاج باستخدام إترانوكس.</p><p dir="RTL">إذا أصبحت حامل بعد بدء دورة شهرية من إترانوكس، فتوقف عن تناوله وأخبر طبيبك على الفور.</p><p dir="RTL">قبل تناول أي دواء - أخبر طبيبك دائمًا إذا كنت حاملاً أو تعتقدين أنك حامل أو تحاولين الحمل.</p><p dir="RTL"><strong>&nbsp;الرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنت مرضعة، لا تتناولي إترانوكس، لأن كميات صغيرة من الدواء قد تكون موجودة في حليب الثدي الخاص بك. إذا أوصى طبيبك باستخدام إترانوكس، فقد يقوم بإجراء فحوصات إضافية أثناء تناولك لهذا الدواء.</p><p dir="RTL"><strong>ا</strong><strong>لقيادة واستعمال الماكينات</strong></p><p dir="RTL">يمكن أن يتسبب إترانوكس أحيانًا في حدوث دوار أو عدم وضوح / ازدواج الرؤية أو فقدان السمع. إذا كانت لديك هذه الأعراض، فلا تقود أو تستخدم الآلات.</p><p dir="RTL"><strong>يحتوي محلول إترانوكس عن طريق الفم على السوربيتول</strong></p><p dir="RTL">يحتوي هذا الدواء على 7920 ملجرام سوربيتول بجرعة 40 مل أي ما يعادل 198 ملجرام في كل مل. إذا أخبرك طبيبك بأنك (أو طفلك) تعاني من عدم تحمل بعض السكريات أو إذا تم تشخيص إصابتك بعدم تحمل الفركتوز الوراثي (HFI)، وهو اضطراب وراثي نادر لا يستطيع فيه الشخص أيض الفركتوز، فتحدث إلى طبيبك قبل أن تتناول (أو طفلك) هذا الدواء. السوربيتول هو مصدر للفركتوز وقد يسبب عدم ارتياح في الجهاز الهضمي وتأثير ملين خفيف.</p><p dir="RTL"><strong>يحتوي محلول إترانوكس عن طريق الفم على البروبيلين جليكول</strong></p><p dir="RTL">يحتوي هذا الدواء على 4.2 جم من البروبيلين جليكول في كل جرعة 40 مل أي ما يعادل 104 ملجرام/ مل. إذا كنت حاملاً أو مرضعة أو تعانين من أمراض الكبد أو الكلى، فلا تتناول هذا الدواء إلا إذا أوصى طبيبك بذلك. قد يقوم طبيبك بإجراء فحوصات إضافية أثناء تناول هذا الدواء.</p><p dir="RTL"><strong>يحتوي محلول إترانوكس عن طريق الفم على سيكلودكسترين</strong></p><p dir="RTL">يحتوي هذا الدواء على 16000 ملجرام سيكلودكسترين (s) في كل 40 مل أي ما يعادل 400 ملجرام / مل. قد يسبب السيكلودكسترين مشاكل في الجهاز الهضمي مثل الإسهال.</p><p dir="RTL"><strong>يحتوي محلول إترانوكس عن طريق الفم على كحول (إيثانول)</strong></p><p dir="RTL">يحتوي هذا الدواء على 0.2 ملجرام من الكحول (إيثانول) في كل جرعة 40 مل أي ما يعادل 0.005 ملجرام/ مل. كمية 40 مل من هذا الدواء تعادل أقل من 1 مل من البيرة أو 1 مل من النبيذ.</p><p dir="RTL">لن يكون للكمية الصغيرة من الكحول في هذا الدواء أي آثار ملحوظة.</p><p dir="RTL"><strong>يحتوي محلول إترانوكس عن طريق الفم على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول صوديوم (23) لكل 40 مل، وهذا يعني بشكل أساسي &quot;خالٍ من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب تناول إترانوكس دائمًا قبل تناول أي طعام أو شراب بساعة واحدة لأن ذلك يساعد الجسم على امتصاص الدواء.</p><p dir="RTL">يجب أن تمضمض المحلول الفموي في فمك لمدة 20 ثانية تقريبًا قبل بلعه. لا تشطف فمك بعد بلع المحلول الفموي.</p><p dir="RTL">دائما تناول إترانوكس تماما كما أخبرك طبيبك. يجب عليك مراجعة طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL">كوب قياس متدرج للإشارة إلى توفير 10 مل. تأكد من ملء الكوب حتى علامة 10 مل.</p><p dir="RTL"><strong>&nbsp;</strong><strong>كيفية تناول إترانوكس محلول عن طريق الفم</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج التهابات الخميرة في الفم أو الحلق أو المريء</p><p dir="RTL">الجرعة المعتادة هي 2 كوب قياس (20 مل) في اليوم لمدة أسبوع. يمكن تناول هذا إما دفعة واحدة أو على جرعتين مقسمتين خلال اليوم.</p><p dir="RTL">إذا لم يتم القضاء على العدوى بعد أسبوع واحد من استخدام إترانوكس<strong>،</strong> فقد يقرر طبيبك مواصلة العلاج لمدة أسبوع آخر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج عدوى الخميرة في الفم أو الحلق أو المريء، والتي تم علاجها بالفعل بمضاد فطري آخر ولكن لم يتم تطهيرها بعد</p><p dir="RTL">الجرعة المعتادة هي 1-2 كوب قياس (10-20 مل) مرتين يوميًا لمدة أسبوعين. قد يستمر العلاج لمدة أسبوعين إضافيين، إذا لم تتضح العدوى في الأسبوعين الأولين من العلاج. بالنسبة للمرضى الذين يتناولون جرعة أعلى من 400 ملجرام (4 أكواب قياس) يوميًا، يجب أن يقتصر العلاج على 14 يومًا، إذا لم تكن هناك علامات تحسن خلال هذا الوقت.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوقاية من الالتهابات الفطرية</p><p dir="RTL">يتم احتساب الجرعة وفقًا لوزن جسمك (5 ملجرام لكل كجم) مقسمة على جرعتين. سيخبرك طبيبك بالضبط بالمقدار الذي يجب أن تتناوله.</p><p dir="RTL"><strong>اتجاهات لفتح الزجاجة</strong></p><p dir="RTL">تأتي الزجاجة بغطاء مقاوم للأطفال، ويجب فتحها على النحو التالي: ادفع الغطاء اللولبي البلاستيكي لأسفل، مع قلبه عكس اتجاه عقارب الساعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية استخدام كوب القياس</strong></p><p dir="RTL">استخدم كوب القياس تمامًا كما هو مثبت على الزجاجة. تأكد من أن الجانب الذي يحتوي على تدرجات (الجانب الذي يحمل أقل) هو الأعلى؛ هذا هو الجانب الذي يجب أن تملأه. عندما يشير السهم الموجود على الجانب لأعلى، يكون الجانب الصحيح هو الأعلى.</p><p dir="RTL">إذا تناولت جرعة زائدة من إترانوكس عن طريق الفم</p><p dir="RTL">&nbsp;إذا كنت أنت أو أي شخص آخر قد تناولت إترانوكس أكثر مما ينبغي، فاتصل بطبيبك أو المستشفى المحلي دون تأخير.</p><p dir="RTL"><strong>إذا نسيت تناول إترانوكس محلول عن طريق الفم</strong></p><p dir="RTL">إذا نسيت تناول الدواء، فتناول الجرعة التالية كالمعتاد واستمر في تناول الدواء حسب توجيهات الطبيب. لا تتناول جرعة مضاعفة.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام إترانوكس، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يتسبب محلول إترانوكس عن طريق الفم في حدوث آثار جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">يمكن أن تسبب الأدوية ردود فعل تحسسية خطيرة. توقف عن تناول إترانوكس واتصل بطبيبك على الفور إذا كان لديك:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي أزيز مفاجئ، أو صعوبة في التنفس، أو انتفاخ في الوجه، أو طفح جلدي، أو حكة (تؤثر بشكل خاص على الجسم كله) أو اضطراب جلدي شديد (طفح جلدي منتشر مع تقشير الجلد وبثور في الفم والعينين والأعضاء التناسلية، أو طفح جلدي مع بثور صغيرة أو بثور).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص حاد في الشهية، والشعور بالغثيان، والمرض، والتعب غير المعتاد، وآلام في البطن (المعدة)، والبول الداكن بشكل غير عادي، أو البراز الشاحب. قد تكون هذه أعراض مشاكل الكبد الحادة.</p><p dir="RTL">يجب عليك أيضًا إخبار طبيبك على الفور إذا كان لديك أي من الآثار الجانبية أدناه:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض تشبه قصور القلب مثل ضيق التنفس وزيادة الوزن بشكل غير متوقع وتورم الساقين والتعب غير المعتاد وتكرار الاستيقاظ ليلاً.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إحساس بالوخز، حساسية للضوء، خدر أو ضعف في الأطراف.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية / الرؤية المزدوجة، طنين في أذنيك، فقدان القدرة على التحكم في البول أو زيادة الحاجة للتبول (تمرير الماء).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أي من أعراض فقدان السمع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام شديدة في الجزء العلوي من المعدة، غالباً مصحوبة بغثيان وقيء بسبب التهاب البنكرياس.</p><p dir="RTL">تشمل الآثار الجانبية الأخرى:</p><p dir="RTL">الآثار الجانبية الشائعة (تظهر لدى أقل من 1 من كل 10 معالجين) هي:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في المعدة، غثيان، (قيء)، إسهال، عسر هضم، طعم مزعج</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى أو ارتفاع في درجة الحرارة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال</p><p dir="RTL">أعراض جانبية غير شائعة (تظهر لدى أقل من مريض واحد من بين كل 100 مريض) هي:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض اضطرابات الدم التي قد تزيد من خطر حدوث نزيف أو كدمات (أعراض محتملة لانخفاض مستويات الصفيحات الدموية)، أو عدوى (أعراض محتملة لانخفاض مستويات خلايا الدم البيضاء)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة، خلايا</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ عام</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلصات العضلات أو عدم انتظام ضربات القلب (الأعراض المحتملة لانخفاض مستويات البوتاسيوم في الدم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام العضلات والمفاصل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف غير طبيعي في الدورة الشهرية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة الإحساس أو الحساسية وخاصة في الجلد</p><p dir="RTL">تم الإبلاغ عن الآثار الجانبية التالية لدى المرضى الذين يتناولون إترانوكس بشيوع غير معروف:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الدهون الثلاثية (الدهون) في الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستويات فوسفوكيناز الكرياتين في الدم</p><p dir="RTL">تم الإبلاغ عن الآثار الجانبية التالية عند المرضى الذين يتناولون تركيبات أخرى من إتراكونازول:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إصابة الجهاز التنفسي العلوي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأنف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجيوب الأنفية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض اضطرابات الدم التي قد تزيد من خطر الإصابة بالعدوى (أعراض محتملة لانخفاض مستويات الخلايا الحبيبية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات السكر في الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلصات العضلات أو عدم انتظام ضربات القلب (الأعراض المحتملة لانخفاض مستويات الماغنيسيوم في الدم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلصات العضلات أو عدم انتظام ضربات القلب (الأعراض المحتملة لارتفاع مستويات البوتاسيوم في الدم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النعاس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتعاش</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة معدل ضربات القلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط دم مرتفع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط دم منخفض</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سوائل في الرئتين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة الكلام</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغازات الزائدة في الأمعاء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادات في اختبارات وظائف الكبد المحددة (زيادة إنزيم الكبد)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد (اليرقان)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعرق الزائد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الكلى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إفراز البول</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الضعف الجنسي لدى الرجال</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ عام</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم صدر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستويات اليوريا في الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج البول غير طبيعية</p><p dir="RTL">&nbsp;</p><p><strong>الإبلاغ عن الآثار الجانبية: </strong></p><p>إن كان لديك أعراض جانبية أو لاحظت أعراض جانبية غير مذكورة في هذه النشرة، فضلًا ابلغ الطبيب أو مقدم الرعاية الصحية أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ هذا الدواء بعيدًا عن رؤية ومتناول أيدي الأطفال.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم إترانوكس بعد تاريخ انتهاء الصلاحية الموجود على الملصق. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من نفس الشهر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يتطلب هذا المنتج الطبي أي ظروف تخزين خاصة بدرجة الحرارة. يجب التخزين في الزجاجة الأصلية لحمايته من الرطوبة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يتطلب هذا الدواء أي شروط تخزين خاصة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من الأدوية في مياه الصرف الصحي. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. هذه التدابير سوف تساعد البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي إيتراكونازول.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي كل مل على 10 ملجرام من إيتراكونازول&nbsp;في محلول مائي</p><p dir="RTL">السواغات الأخرى هي: هيدروكسي بروبيل بيتاديكس (Kleptose HPB)، بروبيلين جليكول، حمض الهيدروكلوريك 37٪، محلول سوربيتول غير متبلور 70٪ (SORBIDEX 71205)، سكرين الصوديوم، نكهة الكرز ART # 349، نكهة الكرز ART # 842، حمض الأسكوربيك وهيدروكسيد الصوديوم (حبيبات، نقية للغاية).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سائل نقي، عديم اللون إلى بني مصفر بنكهة الكرز في زجاجة زجاجية معتمة (النوع الثالث).</p><p dir="RTL"><strong>كيفية توفير إترانوكس محلول فموي؟</strong>:</p><p dir="RTL">يتم توفير إترانوكس في عبوات زجاجية (150 مل).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شركة أماروكس السعودية للصناعة</strong></p><p>شارع الجامعة ، حي الملز</p><p>الرياض 12629 ، المملكة العربية السعودية</p><p>هاتف و فاكس: 966112268850+</p><p><strong>المصنع</strong></p><p dir="RTL">شركة أنورا فارما المحدودة ، الهند.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            
تمت مراجعة هذه النشرة في أكتوبر 2023 ، نسخة 1

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Itranox (Itraconazole Oral Solution 10 mg/mL)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Itranox (Itraconazole Oral Solution 10 mg/mL)

Each ml contains 10mg of ltraconazole in an aqueous solution For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Itranox (Itraconazole Oral Solution 10 mg/mL)
Clear, colorless to yellowish brown liquid having cherry flavor filled in Amber glass (type Ill) bottle.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Itranox Oral Solution is indicated:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for the treatment of oral and/or oesophageal candidosis in HIV-positive or other immunocompromised patients.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as prophylaxis of deep fungal infections anticipated to be susceptible to itraconazole, when standard therapy is considered inappropriate, in patients with haematological malignancy or undergoing bone marrow transplant, and who are expected to become neutropenic (i.e.</p><p>&lt; 500 cells/&micro;L). At present, there are insufficient clinical efficacy data in the prevention of aspergillosis.</p><p>Consideration should be given to national and/or local guidance regarding the appropriate use of antifungal agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For optimal absorption, Itranox Oral Solution should be taken without food (patients are advised to refrain from eating for at least 1 hour after intake).</p><p>For the treatment of oral and/or oesophageal candidosis, the liquid should be swished around the oral cavity (approx. 20 seconds) and swallowed. There should be no rinsing after swallowing.</p><p>&nbsp;</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Treatment of oral and/or oesophageal candidosis:</u> 200 mg (2 measuring cups) per day in two intakes, or alternatively in one intake, for 1 week. If there is no response after 1 week, treatment should be continued for another week.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Treatment of fluconazole resistant oral and/or oesophageal candidosis:</u> 100 to 200 mg (1-2 measuring cups) twice daily for 2 weeks. If there is no response after 2 weeks, treatment should be continued for another 2 weeks. The 400 mg daily dose should not be used for&nbsp; longer than 14 days if there are no signs of improvement.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Prophylaxis of fungal infections:</u> 5 mg/kg per day administered in two intakes. In clinical trials, prophylaxis treatment was started immediately prior to the cytostatic treatment and generally one week before transplant procedure. Almost all proven deep fungal infections occurred in patients reaching neutrophil counts below 100 cells/&micro;L. Treatment was continued until recovery of neutrophils (i.e. &gt; 1 000 cells/&micro;L).</p><p>Pharmacokinetic parameters from clinical studies in neutropenic patients demonstrate considerable intersubject variation. Blood level monitoring should be considered particularly in the presence of gastrointestinal damage, diarrhoea and during prolonged courses of Itranox Oral Solution.</p><p><u>Use in patients with gastro-intestinal motility impairment</u></p><p>When treating patients with severe fungal infections or when administering it as fungal prophylaxis to those with abnormal gastro-intestinal motility, patients should be carefully monitored and where appropriate drug therapeutic monitoring should be considered, where available.</p><p><u>Paediatric population</u></p><p>The safety and efficacy of Itranox Oral Solution in children has not been established. Currently available data are described in section 4.4 and 5.2 but no recommendation on a posology can be made.</p><p>The use of Itranox Oral Solution in paediatric patients is not recommended unless it is determined that the potential benefit outweighs the potential risks (see section 4.4).</p><p>Prophylaxis of fungal infections: there are no efficacy data available in neutropenic children. Limited safety experience is available with a dose of 5 mg/kg per day administered in two intakes. (see section 4.8).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Use in elderly</u></p><p>Since clinical data on the use of ITRANOX Oral Solution in elderly patients are limited, it is advised to use ITRANOX Oral Solution in these patients only if it is determined that the potential benefit outweighs the potential risks. In general, it is recommended that the dose selection for an elderly patient should be taken into consideration, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see section 4.4).</p><p><u>Use in patients with hepatic impairment</u></p><p>Limited data are available on the use of oral itraconazole in patients with hepatic impairment. Caution should be exercised when this drug is administered in this patient population. (see section 5.2)</p><p><u>Use in patients with renal impairment</u></p><p>Limited data are available on the use of oral itraconazole in patients with renal impairment. The exposure of itraconazole may be lower in some patients with renal insufficiency and a wide inter-subject variation was observed in these subjects receiving the capsule formulation (see section 5.2). Caution should be exercised when this drug is administered in this patient population and adjusting the dose or switching to an alternative antifungal medication may be considered based on an evaluation of clinical effectiveness.</p><p><u>Method of administration</u></p><p><em>Precautions to be taken before handling or administering the medicinal product</em></p><p>For instructions on handling of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •		Itranox Oral Solution is contraindicated in patients with a known hypersensitivity to itraconazole or to any of the excipients.
•		Itranox Oral Solution should not be administered to patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF except for the treatment of life-threatening or other serious infections. see 4.4 Special warnings and precautions for use.
•	Itranox Oral Solution must not be used during pregnancy for non-life-threatening indications (see section 4.6).
 

•		Co-administration of a number of CYP3A4 substrates is contraindicated with ITRANOX  Oral Solution (see sections 4.4 and 4.5). These include:
Analgesics; Anaesthetics
Ergot alkaloids
(e.g.	dihydroergotamine, ergometrine,		ergotamine, methylergometrine)		
Anti-bacterials for Systemic Use; Anti-mycobacterials; Antimycotics for Systemic Use
Isavuconazole		
Anthelmintics; Antiprotozoals
Halofantrine		
Antihistamines for Systemic Use
Astemizole	Mizolastine	Terfenadine
Antineoplastic Agents
Irinotecan		
Antithrombotic Agents
Dabigatran	Ticagrelor	
Antivirals for Systemic Use
Ombitasvir/Paritaprevir/Ritonavir (with or without Dasabuvir)		
Cardiovascular System (Agents Acting on the Renin-Angiotensin System; Antihypertensives; Beta Blocking Agents; Calcium Channel Blockers; Cardiac Therapy; Diuretics)
Aliskiren	Dronedarone	Nisoldipine
Bepridil	Eplerenone	Quinidine
Disopyramide	Ivabradine	Ranolazine
 


Dofetilide	
Lercanidipine	Sildenafil (pulmonary hypertension)
Gastrointestinal Drugs, including Antidiarrheals, Intestinal Anti-inflammatory/Anti-infective Agents; Antiemetics and Antinauseants; Drugs for Constipation; Drugs for Functional Gastrointestinal Disorders
Cisapride	Domperidone	Naloxegol
Lipid Modifying Agents
Lovastatin	Lomitapide	Simvastatin
Psychoanaleptics; Psycholeptics (eg, antipsychotics, anxiolytics, and hypnotics)
Lurasidone	Pimozide	Sertindole
Midazolam (oral)	Quetiapine	Triazolam
Urologicals



Avanafil	


Darifenacin	Solifenacin	(in patients with severe renal impairment or moderate to severe hepatic impairment)

Dapoxetine	Fesoterodine (in patients with moderate or severe renal or hepatic impairment).	Vardenafil (in patients older than 75 years).
Miscellaneous Drugs and Other Substances



Colchicine (in patients with renal or hepatic impairment)	Eliglustat (in patients that are CYP2D6 poor metabolisers (PM), CYP2D6 intermediate metabolisers (IMs) or extensive metabolisers (EMs) that are taking a strong or moderate CYP2D6 inhibitor).	

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Use in patients with gastro-intestinal motility impairment</u></p><p>When treating patients with severe fungal infections or when administering it as fungal prophylaxis to those with abnormal gastro-intestinal motility, patients should be carefully monitored and where appropriate drug therapeutic monitoring should be considered, where available.</p><p><u>Cross-hypersensitivity</u></p><p>There is no information regarding cross hypersensitivity between itraconazole and other azole antifungal agents. Caution should be used in prescribing Itranox Oral Solution to patients with hypersensitivity to other azoles.</p><p><u>Cardiac effects</u></p><p>In a healthy volunteer study with Itranox IV, a transient asymptomatic decrease of the left ventricular ejection fraction was observed.</p><p>Itraconazole has been shown to have a negative inotropic effect and Itranox has been associated with reports of congestive heart failure. Heart failure was more frequently reported among spontaneous reports of 400 mg total daily dose than among those of lower total daily doses, suggesting that the risk of heart failure might increase with the total daily dose of itraconazole.</p><p>Itranox should not be used in patients with congestive heart failure or with a history of congestive heart failure unless the benefit clearly outweighs the risk. This individual benefit/risk assessment should take into consideration factors such as the severity of the indication, the dose and duration of treatment, and individual risk factors for congestive heart failure. Such patients should be informed of the signs and symptoms of congestive heart failure, should be treated with caution, and should be monitored for signs and symptoms of congestive heart failure during treatment; if such signs or symptoms do occur during treatment, Itranox should be discontinued. Caution should be exercised when co-administering itraconazole and calcium channel blockers (see section 4.5).</p><p><u>Hepatic effects</u></p><p>Very rare cases of serious hepatotoxicity, including some cases of fatal acute liver failure, have occurred with the use of Itranox. Some of these cases involved patients with no pre-existing liver disease. Some of these cases have been observed within the first month of treatment, including</p><p>&nbsp;</p><p>&nbsp;</p><p>some within the first week. Liver function monitoring should be considered in patients receiving Itranox treatment. Patients should be instructed to promptly report to their physician signs and symptoms suggestive of hepatitis such as anorexia, nausea, vomiting, fatigue, abdominal pain or dark urine. In these patients treatment should be stopped immediately and liver function testing should be conducted. Most cases of serious hepatotoxicity involved patients who had pre- existing liver disease, were treated for systemic indications, had significant other medical conditions and/or were taking other hepatotoxic drugs.</p><p><u>Paediatric population</u></p><p>Clinical data on the use of Itranox Oral Solution in paediatric patients are limited. The use of Itranox Oral Solution in paediatric patients is not recommended unless it is determined that the potential benefit outweighs the potential risks.</p><p><u>Use in elderly</u></p><p>Since clinical data on the use of Itranox Oral Solution in elderly patients is limited, it is advised to use Itranox Oral Solution in these patients only if the potential benefit outweighs the potential risks. In general, it is recommended that the dose selection for an elderly patient should be taken into consideration, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see section 4.4).</p><p><u>Hepatic impairment</u></p><p>Limited data are available on the use of oral itraconazole in patients with hepatic impairment. Caution should be exercised when the drug is administered in this patient population. It is recommended that patients with impaired hepatic function be carefully monitored when taking itraconazole. It is recommended that the prolonged elimination half-life of itraconazole observed in the single oral dose clinical trial with itraconazole capsules in cirrhotic patients be considered when deciding to initiate therapy with other medications metabolised by CYP3A4.</p><p>In patients with elevated or abnormal liver enzymes or active liver disease, or who have experienced liver toxicity with other drugs, treatment with Itranox is strongly discouraged unless there is a serious or life-threatening situation where the expected benefit exceeds the risk. It is recommended that liver function monitoring be done in patients with pre-existing hepatic function abnormalities or those who have experienced liver toxicity with other medications (see section 5.2).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>Limited data are available on the use of oral itraconazole in patients with renal impairment. The exposure of itraconazole may be lower in some patients with renal insufficiency and a wide inter-subject variation was observed in these subjects receiving the capsule formulation (see section 5.2). Caution should be exercised when this drug is administered in this patient population and adjusting the dose or switching to an alternative antifungal medication may be considered based on an evaluation of clinical effectiveness.</p><p><u>Prophylaxis in neutropenic patients</u></p><p>In clinical trials diarrhoea was the most frequent adverse event. This disturbance of the gastrointestinal tract may result in impaired absorption and may alter the microbiological flora potentially favouring fungal colonisation. Consideration should be given to discontinuing Itranox Oral Solution in these circumstances.</p><p><u>Treatment of severely neutropenic patients</u></p><p>Itranox Oral Solution as treatment for oral and/or oesophageal candidosis was not investigated in severely neutropenic patients. Due to the pharmacokinetic properties (see section 5.2), Itranox Oral Solution is not recommended for initiation of treatment in patients at immediate risk of systemic candidosis.</p><p><u>Hearing Loss</u></p><p>Transient or permanent hearing loss has been reported in patients receiving treatment with itraconazole. Several of these reports included concurrent administration of quinidine which is contraindicated (see sections 4.3 and 4.5). The hearing loss usually resolves when treatment is stopped, but can persist in some patients.</p><p><u>Cystic fibrosis</u></p><p>In cystic fibrosis patients, variability in plasma levels of itraconazole leading to subtherapeutic concentrations has been observed. The risk for subtherapeutic concentrations may be higher in &lt; 16 year olds. If a patient does not respond to Itranox oral solution, consideration should be given to switching to Itranox IV or to alternative therapy.</p><p><u>Neuropathy</u></p><p>If neuropathy occurs that may be attributable to Itranox Oral Solution, the treatment should be discontinued.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Cross-resistance</u></p><p>In systemic candidosis, if fluconazole-resistant strains of <em>Candida </em>species are suspected, it cannot be assumed that these are sensitive to itraconazole, hence their sensitivity should be tested before the start of itraconazole therapy.</p><p><u>Interaction potential</u></p><p>Co-administration of specific drugs with itraconazole may result in changes in efficacy or safety of itraconazole and/or the co-administered drug. For example, the use of itraconazole with CYP3A4 inducing agents may lead to sub-therapeutic plasma concentrations of itraconazole and thus treatment failure. In addition, the use of itraconazole with some substrates of CYP3A4 can lead to increases in plasma concentrations of these drugs and to serious and/or potentially life threatening adverse events, such as QT prolongation and ventricular tachyarrhythmias including occurrences of torsade de pointes, a potentially fatal arrhythmia. The prescriber should refer to the co-administered medicinal product information for further information regarding serious or life threatening adverse events that could occur in cases of increased plasma concentrations for that medication. For recommendations concerning the co-administration of medicinal products which are contraindicated, not recommended or recommended for use with caution in combination with itraconazole please refer to sections 4.3 and 4.5.</p><p><u>Interchangeability</u></p><p>It is not recommended that Itranox Capsules and Itranox Oral Solution be used interchangeably. This is because drug exposure is greater with the Oral Solution than with the Capsules when the same dose of drug is given.</p><p><u>Excipients of Itranox Oral Solution</u></p><p>Itranox Oral Solution contains 7 920 mg sorbitol in each 40 mL dose which is equivalent to 198 mg/mL. The additive effect of concomitantly administered products containing sorbitol (or fructose) and dietary intake of sorbitol (or fructose) should be considered. The content of sorbitol in medicinal products for oral use may affect the bioavailability of other medicinal products for oral use administered concomitantly. Patients with hereditary fructose intolerance (HFI) should not take this medicinal product. Sorbitol may cause gastrointestinal discomfort and mild laxative effect.</p><p>&nbsp;</p><p>&nbsp;</p><p>Itranox Oral Solution contains less than 1 mmol sodium (23 mg) per 40 mL dose, that is to say essentially &#39;sodium-free&#39;.</p><p>Itranox Oral Solution contains 0.2 mg of alcohol (ethanol) in each 40 mL dose which is equivalent to 0.005 mg/mL. The amount in 40 mL of this medicine is equivalent to less than 1 mL beer or 1 mL wine. The small amount of alcohol in this medicine will not have any noticeable effects.</p><p>Itranox Oral Solution contains 16 000 mg cyclodextrin(s) in each 40 mL dose which is equivalent to 400 mg/mL. Cyclodextrins may cause digestive problems such as diarrhoea. There is insufficient information on the effects of cyclodextrin in children &lt;2 years old. Therefore, a case by case judgement should be made regarding the risk/benefit for the patient with Itranox Oral Solution (see section 4.2).</p><p>Itranox Oral Solution contains 4.2 g propylene glycol in each 40 mL dose which is equivalent to 104 mg/mL and must not be used during pregnancy except for life-threatening cases where the potential benefit to the mother outweighs the potential harm to the foetus (see section 4.3). Itranox Oral Solution must not be used during lactation (see section 4.6). Co-administration with any substrate for alcohol dehydrogenase such as ethanol may induce adverse effects in children less than 5 years old. Monitoring is required in patients with hepatic or renal impairment because adverse events attributed to propylene glycol have been reported, such as renal dysfunction (acute tubular necrosis), acute renal failure and liver dysfunction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Itraconazole is mainly metabolised through CYP3A4. Other substances that either share this metabolic pathway or modify CYP3A4 activity may influence the pharmacokinetics of itraconazole. Itraconazole is a strong CYP3A4 inhibitor and, a P-glycoprotein inhibitor and Breast Cancer Resistance Protein (BCRP) inhibitor.</p><p>Itraconazole may modify the pharmacokinetics of other substances that share this metabolic or these protein transporter pathways.</p><p>Examples of drugs that may impact on the plasma concentration of itraconazole are presented by drug class in Table 1 below. Examples of drugs that may have their plasma concentrations impacted by itraconazole are presented in Table 2 below. Due to the number of interactions, the</p><p>&nbsp;</p><p>&nbsp;</p><p>potential changes in safety or efficacy of the interacting drugs are not included. Please refer to the prescribing information of the interacting drug for more information.</p><p>The interactions described in these tables are categorised as contraindicated, not recommended or to be used with caution with itraconazole taking into account the extent of the concentration increase and the safety profile of the interacting drug (see also sections 4.3 and 4.4 for further information). The interaction potential of the listed drugs was evaluated based on human pharmacokinetic studies with itraconazole, and/or human pharmacokinetic studies with other strong CYP3A4 inhibitors (e.g. ketoconazole) and/or <em>in vitro </em>data:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#39;Contraindicated&#39;: Under no circumstances is the drug to be co-administered with itraconazole, and up to two weeks after discontinuation of treatment with itraconazole.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#39;Not recommended&#39;: The use of the drug be avoided during and up to two weeks after discontinuation of treatment with itraconazole, unless the benefits outweigh the potentially increased risks of side effects. If co-administration cannot be avoided, clinical monitoring for signs or symptoms of increased or prolonged effects or side effects of the concomitantly administered drug is recommended, and its dosage be reduced or interrupted as deemed necessary. When appropriate, it is recommended that plasma concentrations of the co-administered drug be measured.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#39;Use with caution&#39;: Careful monitoring is recommended when the drug is co-administered with itraconazole. Upon co-administration, it is recommended that patients be monitored closely for signs or symptoms of increased or prolonged effects or side effects of the interacting drug, and its dosage be reduced as deemed necessary. When appropriate, it is recommended that plasma concentrations of the co-administered drug be measured.</p><p>The interactions listed in these tables have been characterised in studies that were performed with recommended doses of itraconazole. However, the extent of interaction may be dependent on the dose of itraconazole administered. A stronger interaction may occur at a higher dose or with a shorter dosing interval. Extrapolation of the findings with other dosing scenarios or different drugs should be done with caution.</p><p>Once treatment is stopped, itraconazole plasma concentrations decrease to an almost undetectable concentration within 7 to 14 days, depending on the dose and duration of treatment. In patients with hepatic cirrhosis or in subjects receiving CYP3A4 inhibitors, the decline in</p><p>&nbsp;</p><p>&nbsp;</p><p>plasma concentrations may be even more gradual. This is particularly important when initiating therapy with drugs whose metabolism is affected by itraconazole. (see section 5.2)</p><p>Table 1: Examples of drugs that may impact the plasma concentration of itraconazole, presented by drug class</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal products Per Orale [PO] Single Dose unless otherwise stated) within class</strong></p></td><td style="vertical-align:top"><p><strong>Expected/Potential&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; effect&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; on itraconazole levels</strong></p><p><strong>(&uarr; = increase; &harr; = no change; &darr; =</strong></p><p><strong>decrease)</strong></p></td><td style="vertical-align:top"><p><strong>Clinical comment</strong></p><p><strong>(see above for additional info and also sections 4.3 and 4.4)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Anti-bacterials for Systemic Use; Anti-mycobacterials</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Isoniazid</p></td><td style="vertical-align:top"><p>Although not studied directly, isoniazid is likely to decrease the concentrations of itraconazole.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Not recommended</p></td></tr><tr><td style="vertical-align:top"><p>Rifampicin PO 600 mg OD</p></td><td style="vertical-align:top"><p>Itraconazole AUC &darr;</p></td><td style="vertical-align:top"><p>Not recommended</p></td></tr><tr><td style="vertical-align:top"><p>Rifabutin PO 300 mg OD</p></td><td style="vertical-align:top"><p>Itraconazole Cmax &darr; 71%, AUC &darr; 74%</p></td><td style="vertical-align:top"><p>Not recommended</p></td></tr><tr><td style="vertical-align:top"><p>Ciprofloxacin PO 500 mg BID</p></td><td style="vertical-align:top"><p>Itraconazole Cmax &uarr; 53%, AUC &uarr; 82%</p></td><td style="vertical-align:top"><p>Use with caution</p></td></tr><tr><td style="vertical-align:top"><p>Erythromycin 1 g</p></td><td style="vertical-align:top"><p>Itraconazole Cmax &uarr; 44%, AUC &uarr; 36%</p></td><td style="vertical-align:top"><p>Use with caution</p></td></tr><tr><td style="vertical-align:top"><p>Clarithromycin PO 500 mg BID</p></td><td style="vertical-align:top"><p>Itraconazole Cmax &uarr; 90%, AUC &uarr; 92%</p></td><td style="vertical-align:top"><p>Use with caution</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antiepileptics</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Carbamazepine, Phenobarbital</p></td><td style="vertical-align:top"><p>Although not studied directly, these drugs are likely to decrease concentrations of itraconazole.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Not recommended</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Phenytoin PO 300 mg OD</p></td><td style="vertical-align:top"><p>Itraconazole Cmax &darr; 83%, AUC &darr; 93% Hydroxyitraconazole Cmax &darr; 84%, AUC &darr; 95%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Not recommended</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antineoplastics Agents</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Idelalisib</p></td><td style="vertical-align:top"><p>Although not studied directly, idelalisib is likely to increase the concentrations of</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use with caution</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>itraconazole.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antivirals for Systemic Use</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Ombitasvir/Paritaprevir/Ritonavir (with or without Dasabuvir)</p></td><td style="vertical-align:top"><p>Although not studied directly, these drugs are expected to increase the concentrations of itraconazole.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Contraindicated</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Efavirenz 600 mg</p></td><td style="vertical-align:top"><p>Itraconazole Cmax &darr; 37%, AUC &darr; 39%; Hydroxyitraconazole Cmax &darr; 35%, AUC &darr; 37%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Not recommended</p></td></tr><tr><td style="vertical-align:top"><p>Nevirapine PO 200 mg OD</p></td><td style="vertical-align:top"><p>Itraconazole Cmax &darr; 38%, AUC &darr; 62%</p></td><td style="vertical-align:top"><p>Not recommended</p></td></tr><tr><td style="vertical-align:top"><p>Cobicistat, Darunavir (boosted), Elvitegravir (ritonavir-boosted), Fosamprenavir&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (ritonavir- boosted), Ritonavir, Saquinavir (ritonavir-boosted)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Although not studied directly, these drugs are expected to increase the concentrations of itraconazole.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Use with caution</p></td></tr><tr><td style="vertical-align:top"><p>Indinavir PO 800 mg TID</p></td><td style="vertical-align:top"><p>Itraconazole concentration &uarr;</p></td><td style="vertical-align:top"><p>Use with caution</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Calcium Channel Blockers</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Diltiazem</p></td><td style="vertical-align:top"><p>Although not studied directly, diltiazem is likely to increase the concentration of itraconazole.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use with caution</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Drugs for Acid Related Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Antacids (aluminium, calcium, magnesium, or sodium bicarbonate),&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; H2-receptor antagonists (eg, cimetidine, ranitidine), Proton pump inhibitors (eg, lansoprazole, omeprazole, rabeprazole)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Itraconazole Cmax &darr;, AUC &darr;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Use with caution</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Respiratory System: Other Respiratory System Products</strong></p></td></tr><tr><td style="vertical-align:top"><p>Lumacaftor/Ivacaftor&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PO 200/250 mg BID</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Itraconazole concentration &darr;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Not recommended</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Miscellaneous</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>St. John&#39;s Wort (<em>Hypericum perforatum</em>)</p></td><td style="vertical-align:top"><p>Although not studied directly, St. John&#39;s Wort is likely to decrease the concentration of itraconazole.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Not recommended</p></td></tr></tbody></table><p>&nbsp;</p><p>Table 2 Examples of drugs that may have their plasma concentrations impacted by itraconazole, presented by drug class</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Medicinal products (PO Single Dose unless otherwise stated) within class</strong></p></td><td style="vertical-align:top"><p><strong>Expected/Potential effect on drug levels</strong></p><p>(&uarr; = increase; &harr; = no change; &darr; =</p><p>decrease)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Clinical comment</strong></p><p><strong>(see above for additional info and also sections 4.3 and 4.4)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Analgesics; Anaesthetics</strong></p></td></tr><tr><td style="vertical-align:top"><p>Ergot&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; alkaloids&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (eg, dihydroergotamine, ergometrine, ergotamine, methylergometrine)</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Contraindicated</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Eletriptan, Fentanyl</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Not recommended</p></td></tr><tr><td style="vertical-align:top"><p>Alfentanil, Buprenorphine (IV and sublingual), Cannabinoids, Methadone, Sufentanil</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use with caution</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Oxycodone PO 10 mg,</p></td><td style="vertical-align:top"><p>Oxycodone PO: Cmax &uarr; 45%, AUC &uarr;</p><p>2.4-fold</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use with caution</p></td></tr><tr><td style="vertical-align:top"><p>Oxycodone IV 0.1 mg/kg</p></td><td style="vertical-align:top"><p>Oxycodone IV: AUC &uarr; 51%</p></td><td style="vertical-align:top"><p>Use with caution</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Anti-bacterials for Systemic Use; Anti-mycobacterials; Antimycotics for Systemic Use</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Isavuconazole</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of isavuconazole.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Contraindicated</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Bedaquiline</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of bedaquiline.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Not recommended</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Rifabutin PO 300 mg OD</p></td><td style="vertical-align:top"><p>Rifabutin concentration &uarr; (extent</p><p>unknown)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Not recommended</p></td></tr><tr><td style="vertical-align:top"><p>Clarithromycin PO 500 mg BID</p></td><td style="vertical-align:top"><p>Clarithromycin concentration &uarr;</p></td><td style="vertical-align:top"><p>Use with caution</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Delamanid</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of delamanid.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use with caution</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antiepileptics</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Carbamazepine</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of carbamazepine.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Not recommended</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Anti-inflammatory and Antirheumatic Products</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Meloxicam 15 mg</p></td><td style="vertical-align:top"><p>Meloxicam Cmax &darr; 64%, AUC &darr;</p><p>37%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use with caution</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Anthelmintics; Antiprotozoals</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Halofantrine</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of halofantrine.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Contraindicated</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Artemether-lumefantrine, Praziquantel</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use with caution</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Quinine 300 mg</p></td><td style="vertical-align:top"><p>Quinine Cmax &harr;, AUC &uarr; 96%</p></td><td style="vertical-align:top"><p>Use with caution</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antihistamines for Systemic Use</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Astemizole,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mizolastine, Terfenadine</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Contraindicated</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Ebastine 20 mg</p></td><td style="vertical-align:top"><p>Ebastine Cmax &uarr; 2.5-fold, AUC &uarr;</p><p>6.2-fold</p><p>Carebastine Cmax &harr;, AUC &uarr; 3.1- fold</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Not recommended</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Bilastine, Rupatadine</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use with caution</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antineoplastic Agents</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Irinotecan</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of irinotecan and its active metabolite.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Contraindicated</p></td></tr><tr><td style="vertical-align:top"><p>Axitinib, Bosutinib, Cabazitaxel, Cabozantinib,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ceritinib, Crizotinib,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dabrafenib,</p><p>Dasatinib,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Docetaxel, Everolimus, Ibrutinib, Lapatinib, Nilotinib,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pazopanib,</p><p>Regorafenib,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sunitinib,</p><p>Temsirolimus,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trabectedin, Trastuzumab emtansine, Vinca alkaloids (eg, vinflunine, vinorelbine)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs except for cabazitaxel and regorafenib. No statistically significant change in cabazitaxel exposure, but a high variability in the results was observed. Regorafenib AUC is expected to decrease (by estimation of active moiety)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Not recommended</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Cobimetinib 10 mg</p></td><td style="vertical-align:top"><p>Cobimetinib Cmax &uarr; 3.2-fold, AUC &uarr;</p><p>6.7-fold</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Not recommended</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Olaparib 100 mg</p></td><td style="vertical-align:top"><p>Olaparib Cmax &uarr; 40%, AUC &uarr; 2.7- fold</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Not recommended</p></td></tr><tr><td style="vertical-align:top"><p>Alitretinoin (oral), Bortezomib, Brentuximab vedotin, Erlotinib, Idelalisib, Imatinib, Nintedanib, Panobinostat,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ponatinib, Ruxolitinib, Sonidegib,</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Use with caution</p></td></tr><tr><td style="vertical-align:top"><p>Busulfan 1 mg/kg Q6h</p></td><td style="vertical-align:top"><p>Busulfan Cmax &uarr;, AUC &uarr;</p></td><td style="vertical-align:top"><p>Use with caution</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Gefitinib 250 mg</p></td><td style="vertical-align:top"><p>Gefitinib 250 mg Cmax &uarr;, AUC &uarr;</p><p>78%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use with caution</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antithrombotic Agents</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Dabigatran, Ticagrelor</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Contraindicated</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Apixaban,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rivaroxaban, Vorapaxar</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Not recommended</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Cilostazol,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Coumarins&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (eg, warfarin)</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use with caution</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antivirals for Systemic Use</strong></p></td></tr><tr><td style="vertical-align:top"><p>Ombitasvir/Paritaprevir/Ritonavir (with or without Dasabuvir)</p></td><td style="vertical-align:top"><p>Itraconazole&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; may&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase paritaprevir concentrations .</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Contraindicated</p></td></tr><tr><td style="vertical-align:top"><p>Elbasvir/Grazoprevir, Simeprevir,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tenofovir</p></td><td style="vertical-align:top"><p>Although&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; not&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; studied&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; directly, itraconazole is likely to increase the</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Not recommended</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>alafenamide fumarate (TAF), Tenofovir disoproxil fumarate (TDF)</p></td><td style="vertical-align:top"><p>concentrations of these drugs.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cobicistat,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elvitegravir (ritonavir-boosted), Glecaprevir/Pibrentasvir, Maraviroc, Ritonavir, Saquinavir</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Use with caution</p></td></tr><tr><td style="vertical-align:top"><p>Indinavir PO 800 mg TID</p></td><td style="vertical-align:top"><p>Indinavir Cmax &harr;, AUC &uarr;</p></td><td style="vertical-align:top"><p>Use with caution</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Cardiovascular System (Agents Acting on the Renin-Angiotensin System; Antihypertensives; Beta Blocking Agents; Calcium Channel Blockers; Cardiac Therapy; Diuretics)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Bepridil,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disopyramide,</p><p>Dofetilide,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dronedarone,</p><p>Eplerenone,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ivabradine,</p><p>Lercanidipine,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nisoldipine, Ranolazine,&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sildenafil (pulmonary hypertension)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Contraindicated</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Aliskiren 150 mg</p></td><td style="vertical-align:top"><p>Aliskiren Cmax &uarr; 5.8-fold, AUC &uarr;</p><p>6.5-fold</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Contraindicated</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Quinidine 100 mg</p></td><td style="vertical-align:top"><p>Quinidine Cmax &uarr; 59%, AUC &uarr; 2.4- fold</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Contraindicated</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Felodipine 5 mg</p></td><td style="vertical-align:top"><p>Felodipine Cmax &uarr; 7.8-fold, AUC &uarr;</p><p>6.3-fold</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Not recommended</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Riociguat, Tadalafil (pulmonary hypertension)</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Not recommended</p></td></tr><tr><td style="vertical-align:top"><p>Bosentan, Diltiazem, Guanfacine, Other&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dihydropyridines&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (eg,</p></td><td style="vertical-align:top"><p>Although&nbsp;&nbsp;&nbsp;&nbsp; not&nbsp;&nbsp;&nbsp;&nbsp; studied&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; directly, itraconazole is likely to increase the</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use with caution</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>amlodipine,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; isradipine,</p><p>nifedipine,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nimodipine), Verapamil</p></td><td style="vertical-align:top"><p>concentrations of bosentan.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Digoxin 0.5 mg</p></td><td style="vertical-align:top"><p>Digoxin Cmax &uarr; 34%, AUC &uarr; 68%</p></td><td style="vertical-align:top"><p>Use with caution</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Nadolol 30 mg</p></td><td style="vertical-align:top"><p>Nadolol Cmax &uarr; 4.7-fold, AUC &uarr; 2.2- fold</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use with caution</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Corticosteroids for Systemic Use; Drugs for Obstructive Airway Diseases</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Ciclesonide, Salmeterol</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of salmeterol and the active metabolite of ciclesonide.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Not recommended</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Budesonide INH 1 mg SD</p></td><td style="vertical-align:top"><p>Budesonide INH Cmax&nbsp; &uarr; 65%, &nbsp;AUC</p><p>&uarr;&nbsp;&nbsp;&nbsp;&nbsp; 4.2-fold;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Budesonide&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (other</p><p>formulations) concentration &uarr;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use with caution</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Dexamethasone IV 5 mg Dexamethasone PO 4.5 mg</p></td><td style="vertical-align:top"><p>Dexamethasone IV: Cmax &harr;, AUC &uarr;</p><p>3.3-fold</p><p>Dexamethasone PO: Cmax &uarr; 69%, AUC &uarr; 3.7-fold</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Use with caution</p></td></tr><tr><td style="vertical-align:top"><p>Fluticasone INH 1 mg BID</p></td><td style="vertical-align:top"><p>Fluticasone INH concentration &uarr;</p></td><td style="vertical-align:top"><p>Use with caution</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Methylprednisolone 16 mg</p></td><td style="vertical-align:top"><p>Methylprednisolone&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PO&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cmax &uarr; 92%, AUC &uarr; 3.9-fold Methylprednisolone IV AUC &uarr; 2.6- fold</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Use with caution</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Fluticasone nasal</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of nasally- administered fluticasone.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Use with caution</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Drugs Used in Diabetes</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Repaglinide 0.25 mg</p></td><td style="vertical-align:top"><p>Repaglinide Cmax &uarr; 47%, AUC &uarr;</p><p>41%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use with caution</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Saxagliptin</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of saxagliptin.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use with caution</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Gastrointestinal Drugs, including Antidiarrheals, Intestinal Anti-inflammatory/Anti-infective Agents; Antiemetics and Antinauseants; Drugs for Constipation; Drugs for Functional Gastrointestinal Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Cisapride, Naloxegol</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Contraindicated</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Domperidone 20 mg</p></td><td style="vertical-align:top"><p>Domperidone Cmax &uarr; 2.7-fold, AUC</p><p>&uarr; 3.2-fold</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Contraindicated</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Aprepitant,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loperamide, Netupitant</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of aprepitant.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use with caution</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Immunosuppressants</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Sirolimus (rapamycin)</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of sirolimus.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Not recommended</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Cyclosporine, Tacrolimus</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of cyclosporine.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use with caution</p></td></tr><tr><td style="vertical-align:top"><p>Tacrolimus IV 0.03 mg/kg OD</p></td><td style="vertical-align:top"><p>Tacrolimus IV concentration &uarr;</p></td><td style="vertical-align:top"><p>Use with caution</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Lipid Modifying Agents</strong></p></td></tr><tr><td style="vertical-align:top"><p>Lomitapide</p></td><td style="vertical-align:top"><p>Although&nbsp;&nbsp;&nbsp;&nbsp; not&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; studied&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; directly,</p></td><td style="vertical-align:top"><p>Contraindicated</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>itraconazole is likely to increase the concentrations of lomitapide.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Lovastatin 40 mg,</p></td><td style="vertical-align:top"><p>Lovastatin&nbsp;&nbsp;&nbsp; Cmax &uarr;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 14.5-&gt;20-fold, AUC &uarr; &gt;14.8 - &gt;20-fold</p><p>Lovastatin acid Cmax &uarr; 11.5-13-fold, AUC &uarr; 15.4-20-fold</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Contraindicated</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Simvastatin 40 mg</p></td><td style="vertical-align:top"><p>Simvastatin&nbsp;&nbsp; acid&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cmax &uarr;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17-fold, AUC &uarr; 19-fold</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Contraindicated</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Atorvastatin</p></td><td style="vertical-align:top"><p>Atorvastatin acid: Cmax &harr; to &uarr;2.5- fold, AUC &uarr; 40% to 3-fold</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Not recommended</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Psychoanaleptics; Psycholeptics (eg, antipsychotics, anxiolytics, and hypnotics)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Lurasidone,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pimozide, Quetiapine, Sertindole</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Contraindicated</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Midazolam (oral) 7.5 mg</p></td><td style="vertical-align:top"><p>Midazolam (oral) Cmax &uarr; 2.5 to 3.4- fold, AUC &uarr; 6.6 to 10.8-fold</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Contraindicated</p></td></tr><tr><td style="vertical-align:top"><p>Triazolam 0.25 mg</p></td><td style="vertical-align:top"><p>Triazolam Cmax &uarr;, AUC &uarr;</p></td><td style="vertical-align:top"><p>Contraindicated</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Alprazolam 0.8 mg</p></td><td style="vertical-align:top"><p>Alprazolam Cmax &harr;, AUC &uarr; 2.8- fold</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use with caution</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Aripiprazole 3 mg</p></td><td style="vertical-align:top"><p>Aripiprazole Cmax &uarr; 19%, AUC &uarr;</p><p>48%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use with caution</p></td></tr><tr><td style="vertical-align:top"><p>Brotizolam 0.5 mg</p></td><td style="vertical-align:top"><p>Brotizolam Cmax &harr;, AUC &uarr; 2.6-fold</p></td><td style="vertical-align:top"><p>Use with caution</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Buspirone 10 mg</p></td><td style="vertical-align:top"><p>Buspirone Cmax &uarr; 13.4-fold, AUC &uarr;</p><p>19.2-fold</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use with caution</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Midazolam (iv) 7.5 mg</p></td><td style="vertical-align:top"><p>Midazolam&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mg:</p><p>concentration &uarr;;</p><p>Although&nbsp;&nbsp;&nbsp;&nbsp; not&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; studied&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; directly,</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use with caution</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>itraconazole is likely to increase the concentrations of midazolam following&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oromucosal administration.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Risperidone 2-8 mg/day</p></td><td style="vertical-align:top"><p>Risperidone and active metabolite</p><p>concentration &uarr;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use with caution</p></td></tr><tr><td style="vertical-align:top"><p>Zopiclone 7.5 mg</p></td><td style="vertical-align:top"><p>Zopiclone Cmax &uarr; 30%, AUC &uarr; 70%</p></td><td style="vertical-align:top"><p>Use with caution</p></td></tr><tr><td style="vertical-align:top"><p>Cariprazine,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Galantamine,</p><p>Haloperidol,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reboxetine, Venlafaxine</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use with caution</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Respiratory System: Other Respiratory System Products</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Lumacaftor/Ivacaftor&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PO 200/250 mg BID</p></td><td style="vertical-align:top"><p>Ivacaftor Cmax &uarr; 3.6-fold, AUC &uarr;</p><p>4.3-fold</p><p>Lumacaftor Cmax &harr;, AUC &harr;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Not recommended</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Ivacaftor</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of ivacaftor.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use with caution</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Sex Hormones and Modulators of the Genital System; Other Gynaecologicals</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Cabergoline,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dienogest, Ulipristal</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use with caution</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Urologicals</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Avanafil,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dapoxetine, Darifenacin</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Contraindicated</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Fesoterodine</p></td><td style="vertical-align:top"><p>Although&nbsp;&nbsp;&nbsp;&nbsp; not&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; studied&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; directly, itraconazole is likely to increase the</p></td><td style="vertical-align:top"><p>Moderate or severe renal or hepatic&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impairment:</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>concentrations of the active metabolites, 5-hydroxymethyl tolterodine.</p></td><td style="vertical-align:top"><p>Contraindicated</p><p>Mild renal or hepatic impairment: Concomitant use should be avoided</p><p>Normal renal or hepatic function: Use with caution with a maximum fesoterodine dose of 4 mg.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Solifenacin</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Although not studied directly, itraconazole is likely to increase the concentrations of solifenacin.</p></td><td style="vertical-align:top"><p>Severe&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; renal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impairment: Contraindicated</p><p>Moderate&nbsp;&nbsp; or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hepatic impairment: Contraindicated Use with caution in all other patients&nbsp;&nbsp;&nbsp; with&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; maximum solifenacin dose of 5 mg.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Vardenafil</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of vardenafil.</p></td><td style="vertical-align:top"><p>Contraindicated in patients older than 75 years; otherwise not recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Alfuzosin, Silodosin, Tadalafil (erectile dysfunction and benign prostatic&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hyperplasia), Tamsulosin, Tolterodine</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Not recommended</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Dutasteride,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Imidafenacin, Sildenafil (erectile dysfunction)</p></td><td style="vertical-align:top"><p>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use with caution</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Oxybutynin 5 mg</p></td><td style="vertical-align:top"><p>Oxybutynin Cmax &uarr; 2-fold, AUC &uarr;</p><p>2-fold</p><p>N-desethyloxybutynin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cmax &harr;,</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use with caution</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>AUC &harr;</p><p>Following&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; transdermal administration:</p><p>Although not studied directly, itraconazole is likely to increase the concentrations of oxybutynin following&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; transdermal administration.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Miscellaneous Drugs and Other Substances</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Colchicine</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Although not studied directly, itraconazole is likely to increase the concentrations of colchicine</p></td><td style="vertical-align:top"><p>Contraindicated in&nbsp; patients with renal or hepatic impairment. Not recommended in other patients.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Eliglustat</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Although not directly studied, itraconazole is expected to increase the concentrations of eliglustat.</p></td><td style="vertical-align:top"><p>Contraindicated in CYP2D6 poor metabolisers (PM).</p><p>Contraindicated in CYP2D6 intermediate&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; metabolisers (IMs) or extensive metabolisers (EMs) taking a strong or moderate CYP2D6 inhibitor.</p><p>Use with caution in CYP2D6 IMs and EMs.</p><p>In CYP2D6 EMs with mild hepatic impairment, an eliglustat dose of 84 mg/day should be considered.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Cinacalcet</p></td><td style="vertical-align:top"><p>Although&nbsp;&nbsp;&nbsp;&nbsp; not&nbsp;&nbsp;&nbsp;&nbsp; studied&nbsp;&nbsp;&nbsp; directly, itraconazole is likely to increase the</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Use with caution</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>concentrations of cinacalcet.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Itranox Oral Solution must not be used during pregnancy except for life-threatening cases where the potential benefit to the mother outweighs the potential harm to the foetus (see section 4.3).</p><p>In animal studies itraconazole has shown reproduction toxicity (see section 5.3).</p><p>Epidemiological data on exposure to Itranox during the first trimester of pregnancy &ndash; mostly in patients receiving short-term treatment for vulvovaginal candidosis &ndash; did not show an increased risk for malformations as compared to control subjects not exposed to any known teratogens. Itraconazole has been shown to cross the placenta in a rat model.</p><p><u>Women of childbearing potential</u></p><p>Women of childbearing potential taking Itranox Oral Solution should use contraceptive precautions. Effective contraception should be continued until the menstrual period following the end of Itranox therapy.</p><p><u>Breast-feeding</u></p><p>A very small amount of itraconazole is excreted in human milk. Itranox Oral Solution must not be used during lactation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. When driving vehicles and operating machinery the possibility of adverse reactions such as dizziness, visual disturbances and hearing loss (see section 4.8), which may occur in some instances, must be taken into account.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Summary of the safety profile</em></p><p>The most frequently reported adverse drug reactions (ADRs) with Itranox Oral Solution treatment identified from clinical trials and/or from spontaneous reporting were dizziness, headache, dysgeusia, dyspnoea, cough, abdominal pain, diarrhoea, vomiting, nausea, dyspepsia, rash, and pyrexia. The most serious ADRs were serious allergic reactions, cardiac failure/congestive heart failure/pulmonary oedema, pancreatitis, serious hepatotoxicity</p><p>&nbsp;</p><p>&nbsp;</p><p>(including some cases of fatal acute liver failure), and serious skin reactions. Refer&nbsp; to&nbsp; subsection <em>Tabulated list of adverse reactions </em>for the frequencies and for other observed ADRs. Refer to section 4.4 (Special warnings and precautions for use) for additional information on other serious effects.</p><p><em>Tabulated list of adverse reactions</em></p><p>The ADRs in the table below were derived from double-blind and open-label clinical trials with Itranox Oral Solution involving 889 patients for the treatment of oropharyngeal and oesophageal candidiasis, and from spontaneous reporting.</p><p>The table below presents ADRs by System Organ Class. Within each System Organ Class, the ADRs are presented by incidence, using the following convention:</p><p>Very common (&ge; 1/10); Common (&ge; 1/100 to &lt; 1/10); Uncommon (&ge; 1/1 000 to &lt; 1/100); Rare (&ge; 1/10 000 to &lt; 1/1 000); Very rare (&lt; 1/10 000), Not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Adverse Drug Reactions</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Leukopenia, Thrombocytopenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Hypersensitivity*</p></td></tr><tr><td style="vertical-align:top"><p><em>Not Known</em></p></td><td style="vertical-align:top"><p>Serum sickness, Angioneurotic oedema, Anaphylactic reaction</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Hypokalaemia</p></td></tr><tr><td style="vertical-align:top"><p><em>Not Known</em></p></td><td style="vertical-align:top"><p>Hypertriglyceridaemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Dizziness, Headache, Dysgeusia</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Peripheral neuropathy*, Paraesthesia, Hypoaesthesia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Visual disturbances (including diplopia and blurred vision)</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Tinnitus</p></td></tr><tr><td style="vertical-align:top"><p><em>Not Known</em></p></td><td style="vertical-align:top"><p>Transient or permanent hearing loss*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Cardiac failure</p></td></tr><tr><td style="vertical-align:top"><p><em>Not Known</em></p></td><td style="vertical-align:top"><p>Congestive heart failure*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Dyspnoea, Cough</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Abdominal pain, Diarrhoea, Vomiting, Nausea, Dyspepsia</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Constipation</p></td></tr><tr><td style="vertical-align:top"><p><em>Not Known</em></p></td><td style="vertical-align:top"><p>Pancreatitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Hepatic failure*, Hyperbilirubinaemia</p></td></tr><tr><td style="vertical-align:top"><p><em>Not Known</em></p></td><td style="vertical-align:top"><p>Serious hepatotoxicity (including some cases of fatal acute liver failure)*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Rash</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Urticaria, Pruritus</p></td></tr><tr><td style="vertical-align:top"><p><em>Not Known</em></p></td><td style="vertical-align:top"><p>Toxic epidermal necrolysis, Stevens-Johnson syndrome, Acute generalised exanthematous pustulosis, Erythema multiforme, Exfoliative dermatitis, Leukocytoclastic vasculitis, Alopecia, Photosensitivity</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Myalgia, Arthralgia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Menstrual disorders</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Pyrexia</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Oedema</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Not Known</em></p></td><td style="vertical-align:top"><p>Blood creatine phosphokinase increased</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>* </strong>see section 4.4.</p><p><em>Description of selected adverse reactions</em></p><p>The following is a list of additional ADRs associated with itraconazole that have been reported in clinical trials of Itranox Capsules and Itranox IV, excluding the ADR term &ldquo;Injection site inflammation&rdquo;, which is specific to the injection route of administration.</p><p><strong>Infections and infestations: </strong>Sinusitis, Upper respiratory tract infection, Rhinitis</p><p><strong>Blood and lymphatic system disorders: </strong>Granulocytopenia</p><p><strong>Immune system disorders: </strong>Anaphylactoid reaction</p><p><strong>Metabolism and nutrition disorders: </strong>Hyperglycaemia, Hyperkalaemia, Hypomagnesaemia</p><p><strong>Psychiatric disorders: </strong>Confusional state</p><p><strong>Nervous system disorders: </strong>Somnolence, Tremor <strong>Cardiac disorders: </strong>Left ventricular failure, Tachycardia <strong>Vascular disorders: </strong>Hypertension, Hypotension</p><p><strong>Respiratory, thoracic and mediastinal disorders: </strong>Pulmonary oedema, Dysphonia</p><p><strong>Gastrointestinal disorders: </strong>Gastrointestinal disorder, Flatulence <strong>Hepatobiliary disorders: </strong>Hepatitis, Jaundice, Hepatic function abnormal <strong>Skin and subcutaneous tissue disorders: </strong>Rash erythematous, Hyperhidrosis</p><p><strong>Renal and urinary disorders: </strong>Renal impairment, Pollakiuria, Urinary incontinence</p><p><strong>Reproductive system and breast disorders: </strong>Erectile dysfunction</p><p><strong>General disorders and administration site conditions: </strong>Generalised oedema, Face oedema, Chest pain, Pain, Fatigue, Chills</p><p><strong>Investigations: </strong>Alanine aminotransferase increased, Aspartate aminotransferase increased, Blood alkaline phosphatase increased, Blood lactate dehydrogenase increased, Blood urea</p><p>&nbsp;</p><p>&nbsp;</p><p>increased, Gamma-glutamyltransferase increased, Hepatic enzyme increased, Urine analysis abnormal</p><p><em>Paediatric Population</em></p><p>The safety of Itranox oral solution was evaluated in 250 paediatric patients aged 6 months to 14 years who participated in five open-label clinical trials. These patients received at least one dose of Itranox oral solution for prophylaxis of fungal infections or for treatment of oral thrush or systemic fungal infections and provided safety data.</p><p>Based on pooled safety data from these clinical trials, the very common reported ADRs in paediatric patients were Vomiting (36.0%), Pyrexia (30.8%), Diarrhoea (28.4%), Mucosal inflammation (23.2%), Rash (22.8%), Abdominal pain (17.2%), Nausea (15.6%), Hypertension (14.0%), and Cough (11.2%). The nature of ADRs in paediatric patients is similar to that observed in adult subjects, but the incidence is higher in the paediatric patients.</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions (see details below)</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>&bull;&nbsp; Saudi Arabia<em>:</em></p><p><strong><em>&nbsp;</em></strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:122.9pt;margin-top:9.55pt;width:402.4pt;height:106.95pt;
  z-index:-251655168;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".16969mm">
  <v:textbox style='mso-next-textbox:#_x0000_s1026' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:.05pt;margin-right:81.7pt;
     margin-bottom:0cm;margin-left:10.3pt;margin-bottom:.0001pt;line-height:
     192%'>The National Pharmacovigilance and Drug Safety Centre (NPC) o SFDA
     Call Center: 19999<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.15pt;margin-right:0cm;margin-bottom:
     0cm;margin-left:19.3pt;margin-bottom:.0001pt;text-indent:-9.2pt;
     mso-list:l0 level1 lfo1;tab-stops:19.35pt'><![if !supportLists]><span
     style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span><![endif]><span dir=LTR></span><a
     href="mailto:npc.drug@sfda.gov.sa"><span style='color:windowtext;
     text-decoration:none;text-underline:none'>E-mail:npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:6.85pt;margin-right:0cm;margin-bottom:
     0cm;margin-left:19.3pt;margin-bottom:.0001pt;text-indent:-9.2pt;
     mso-list:l0 level1 lfo1;tab-stops:19.35pt'><![if !supportLists]><span
     style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span><![endif]><span dir=LTR></span>Website:https://ade.sfda.gov.sa/<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="541" height="146" alt="Text Box: The National Pharmacovigilance and Drug Safety Centre (NPC) o SFDA Call Center: 19999
o	E-mail:npc.drug@sfda.gov.sa
o	Website:https://ade.sfda.gov.sa/
" src="file:///C:/Users/Muhammed/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong><em>&nbsp;</em></strong></p><p><strong>o Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p>&nbsp;</p><p>&nbsp;</p><p>In general, adverse events reported with overdose have been consistent with adverse drug reactions already listed in this SmPC for itraconazole (see section 4.8).</p><p><u>Treatment</u></p><p>In the event of an overdose, supportive measures should be employed. Itraconazole cannot be removed by haemodialysis. No specific antidote is available.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antimycotic for systemic use, triazole derivative. ATC code: J02A C02</p><p><u>Mechanism of action</u></p><p>Itraconazole inhibits fungal 14-alpha-demethylase, resulting in a depletion of ergosterol and disruption of membrane synthesis by fungi.</p><p><u>PK/PD relationship</u></p><p>The PK/PD relationship for itraconazole, and for triazoles in general, is poorly understood and is complicated by limited understanding of antifungal pharmacokinetics.</p><p><u>Mechanism(s) of resistance</u></p><p>Resistance of fungi to azoles appears to develop slowly and is often the result of several genetic mutations. Mechanisms that have been described are:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Over-expression of <em>ERG11</em>, the gene that encodes 14-alpha-demethylase (the target enzyme)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Point mutations in <em>ERG11 </em>that lead to decreased affinity of 14-alpha-demethylase for itraconazole</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; Drug-transporter over-expression resulting in increased efflux of itraconazole from fungal cells (i.e., removal of itraconazole from its target)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cross-resistance. Cross-resistance amongst members of the azole class of drugs has been observed within <em>Candida </em>species though resistance to one member of the class does not necessarily confer resistance to other azoles.</p><p><u>Breakpoints</u></p><p>Breakpoints for itraconazole have not yet been established for fungi using EUCAST methods.</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;mso-bidi-font-size:12.0pt'><span style='mso-element:
field-begin;mso-field-lock:yes'></span><span style='mso-spacerun:yes'> </span>SHAPE
<span style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="_x0000_s2050"
 style='width:468pt;height:.75pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="9360,15">
 <v:line id="_x0000_s2051" style='position:absolute' from="0,8" to="9360,8"/>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="625" height="2" src="file:///C:/Users/Muhammed/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;mso-bidi-font-size:12.0pt'><v:shape id="_x0000_i1025"
 type="#_x0000_t75" style='width:468pt;height:.75pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>Using&nbsp;&nbsp; CLSI&nbsp;&nbsp; methods,&nbsp;&nbsp; breakpoints&nbsp;&nbsp; for&nbsp;&nbsp;&nbsp; itraconazole&nbsp;&nbsp;&nbsp; have&nbsp;&nbsp;&nbsp; only&nbsp;&nbsp;&nbsp; been&nbsp;&nbsp;&nbsp; established&nbsp;&nbsp;&nbsp; for <em>Candida </em>species from superficial mycotic infections. The&nbsp; CLSI&nbsp; breakpoints&nbsp; are:&nbsp; susceptible <u>&le;</u>0.125 mg/L and resistant &ge;1 mg/L.</p><p>The prevalence of acquired resistance may vary geographically and with time for selected species, and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><p>The <em>in vitro </em>susceptibility of fungi to itraconazole depends on the inoculum size, incubation temperature, growth phase of the fungi, and the culture medium used. For these reasons, the minimum inhibitory concentration of itraconazole may vary widely. Susceptibility in the table below&nbsp; is&nbsp; based&nbsp; on&nbsp; MIC90 &lt;&nbsp; 1&nbsp; mg&nbsp; itraconazole/L.&nbsp; There&nbsp; is&nbsp; no&nbsp; correlation&nbsp; between <em>in&nbsp;&nbsp;&nbsp; </em><em>vitro </em>susceptibility and clinical efficacy.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Commonly susceptible species</strong></p></td></tr><tr><td style="vertical-align:top"><p>Aspergillus spp.2</p></td></tr><tr><td style="vertical-align:top"><p><em>Blastomyces dermatitidis</em>1</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida albicans</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Candida parapsilosis</em></p></td></tr><tr><td style="vertical-align:top"><p>Cladosporium spp.</p></td></tr><tr><td style="vertical-align:top"><p><em>Coccidioides immitis</em>1</p></td></tr><tr><td style="vertical-align:top"><p><em>Cryptococcus neoformans</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Epidermophyton floccosum</em></p></td></tr><tr><td style="vertical-align:top"><p>Fonsecaea spp. 1</p></td></tr><tr><td style="vertical-align:top"><p>Geotrichum spp.</p></td></tr><tr><td style="vertical-align:top"><p>Histoplasma spp.</p></td></tr><tr><td style="vertical-align:top"><p>Malassezia (formerly Pityrosporum<em>) </em>spp.</p></td></tr><tr><td style="vertical-align:top"><p>Microsporum spp.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Paracoccidioides brasiliensis</em>1</p></td></tr><tr><td style="vertical-align:top"><p><em>Penicillium marneffei</em>1</p></td></tr><tr><td style="vertical-align:top"><p><em>Pseudallescheria boydii</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Sporothrix schenckii</em></p></td></tr><tr><td style="vertical-align:top"><p>Trichophyton spp<em>.</em></p></td></tr><tr><td style="vertical-align:top"><p>Trichosporon spp.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Species for which acquired resistance may be a problem</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Candida glabrata</em>3</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida krusei</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Candida tropicalis</em>3</p></td></tr><tr><td style="vertical-align:top"><p><strong>Inherently resistant organisms</strong></p></td></tr><tr><td style="vertical-align:top"><p>Absidia spp.</p></td></tr><tr><td style="vertical-align:top"><p>Fusarium spp.</p></td></tr><tr><td style="vertical-align:top"><p>Mucor spp.</p></td></tr><tr><td style="vertical-align:top"><p>Rhizomucor spp.</p></td></tr><tr><td style="vertical-align:top"><p>Rhizopus spp.</p></td></tr><tr><td style="vertical-align:top"><p><em>Scedosporium proliferans</em></p></td></tr><tr><td style="vertical-align:top"><p>Scopulariopsis spp.</p></td></tr></tbody></table><p>1 These organisms may be encountered in patients who have returned from travel outside Europe.</p><p>2 Itraconazole-resistant strains of <em>Aspergillus fumigatus </em>have been reported.</p><p>3 Natural intermediate susceptibility.</p><p><em>Paediatric Population</em></p><p>The tolerability and safety of itraconazole oral solution was studied in the prophylaxis of fungal infections in 103 neutropenic paediatric patients aged 0 to14 years (median 5 years) in an open- label uncontrolled phase III clinical study. Most patients (78%) were undergoing allogenic bone marrow transplantation for haematological malignancies. All patients received 5 mg/kg/day of</p><p>&nbsp;</p><p>&nbsp;</p><p>itraconazole oral solution as a single or divided dose. Due to the design of the study, no formal conclusion with regard to efficacy could be derived. The most common adverse events considered definitely for possibly related to itraconazole were vomiting, abnormal liver function, and abdominal pain.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Itraconazole</u></p><p><u>General pharmacokinetic characteristics</u></p><p>Peak plasma concentrations are reached within 2.5 hours following administration of the oral solution. As a consequence of non-linear pharmacokinetics, itraconazole accumulates in plasma during multiple dosing. Steady-state concentrations are generally reached within about 15 days, with Cmax and AUC values 4 to 7-fold higher than those seen after a single dose. Steady-state Cmax values of about 2 &mu;g/mL are reached after oral administration of 200 mg once daily. The terminal half-life of itraconazole generally ranges from 16 to 28 hours after single dose and increases to 34 to 42 hours with repeated dosing. Once treatment is stopped, itraconazole plasma concentrations decrease to an almost undetectable concentration within 7 to 14 days, depending on the dose and duration of treatment. Itraconazole mean total plasma clearance following intravenous administration is 278 mL/min. Itraconazole clearance decreases at higher doses due to saturable hepatic metabolism.</p><p><u>Absorption</u></p><p>Itraconazole is rapidly absorbed after administration of the Oral Solution. Peak plasma concentrations of itraconazole are reached within 2.5 hours following administration of the Oral Solution under fasting conditions. The observed absolute bioavailability of itraconazole under fed conditions is about 55% and increases by 30% when the Oral Solution is taken in fasting conditions. Itraconazole exposure is greater with the Oral Solution than with the Capsule formulation when the same dose of drug is given (see section 4.4).</p><p><u>Distribution</u></p><p>Most of the itraconazole in plasma is bound to protein (99.8%) with albumin being the main binding component (99.6% for the hydroxy- metabolite). It has also a marked affinity for lipids. Only 0.2% of the itraconazole in plasma is present as free drug. Itraconazole is distributed in a large apparent volume in the body (&gt; 700 L), suggesting extensive distribution into tissues:</p><p>&nbsp;</p><p>&nbsp;</p><p>Concentrations in lung, kidney, liver, bone, stomach, spleen and muscle were found to be two to three times higher than corresponding concentrations in plasma, and the uptake into keratinous tissues, skin in particular, up to four times higher. Concentrations in the cerebrospinal fluid are much lower than in plasma, but efficacy has been demonstrated against infections present in the cerebrospinal fluid.</p><p><u>Metabolism</u></p><p>Itraconazole is extensively metabolised by the liver into&nbsp; a&nbsp; large&nbsp; number&nbsp; of&nbsp; metabolites. <em>In vitro </em>studies have shown that CYP3A4 is the major enzyme involved in the metabolism of itraconazole. The main metabolite is hydroxy-itraconazole, which has <em>in vitro </em>antifungal activity comparable to itraconazole; trough plasma concentrations of this metabolite are about twice those of itraconazole.</p><p><u>Elimination</u></p><p>Itraconazole is excreted mainly as inactive metabolites in urine (35%) and in faeces (54%) within one week of an oral solution dose. Renal excretion of itraconazole and the active metabolite hydroxy-itraconazole account for less than 1% of an intravenous dose. Based on an oral radiolabelled dose, faecal excretion of unchanged drug ranges from 3% to 18% of the dose. As re-distribution of itraconazole from keratinous tissues appears to be negligible, elimination of itraconazole from these tissues is related to epidermal regeneration. Contrary to plasma, the concentration in skin persists for 2 to 4 weeks after discontinuation of a 4-week treatment and in nail keratin &ndash; where itraconazole can be detected as early as 1 week after start of treatment &ndash; for at least six months after the end of a 3-month treatment period.</p><p><u>Special Populations</u></p><p><em>Hepatic Impairment</em></p><p>Itraconazole is predominantly metabolised in the liver. A pharmacokinetic study was conducted in 6 healthy and 12 cirrhotic subjects who were administered a single 100-mg dose of itraconazole as a capsule. A statistically significantly reduction in average Cmax (47%) and a two- fold increase in the elimination half-life (37 &plusmn; 17 versus 16 &plusmn; 5 hours) of itraconazole were noted in cirrhotic subjects compared with healthy subjects. However, overall exposure to itraconazole, based on AUC, was similar in cirrhotic patients and in healthy subjects. Data are not available in cirrhotic patients during long-term use of itraconazole (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Renal Impairment</em></p><p>Limited data are available on the use of oral itraconazole in patients with renal impairment.</p><p>A pharmacokinetic study using a single 200-mg dose of itraconazole (four 50-mg capsules) was conducted in three groups of patients with renal impairment (uraemia: n=7; haemodialysis: n=7; and continuous ambulatory peritoneal dialysis: n=5). In uremic subjects with a mean creatinine clearance of 13 mL/min. &times; 1.73 m2, the exposure, based on AUC, was slightly reduced compared with normal population parameters. This study did not demonstrate any significant effect of haemodialysis or continuous ambulatory peritoneal dialysis on the pharmacokinetics of itraconazole (Tmax, Cmax, and AUC0-8h). Plasma concentration-versus-time profiles showed wide intersubject variation in all three groups.</p><p>After a single intravenous dose, the mean terminal half-lives of itraconazole in patients with mild (defined in this study as CrCl 50-79 mL/min), moderate (defined in this study as CrCl 20-49 mL/min), and severe renal impairment (defined in this study as CrCl &lt;20 mL/min) were similar to that in healthy subjects (range of means 42-49 hours vs 48 hours in renally impaired patients and healthy subjects, respectively). Overall exposure to itraconazole, based on AUC, was decreased in patients with moderate and severe renal impairment by approximately 30% and 40%, respectively, as compared with subjects with normal renal function.</p><p>Data are not available in renally impaired patients during long-term use of itraconazole. Dialysis has no effect on the half-life or clearance of itraconazole or hydroxy-itraconazole (see sections 4.2 and 4.4).</p><p><em>Paediatric Population</em></p><p>Two pharmacokinetic studies have been conducted in neutropenic children aged 6 months to 14 years in which itraconazole oral solution was administered 5 mg/kg once or twice daily. The exposure to itraconazole was somewhat higher in older children (6 to 14 years) compared to younger children. In all children, effective plasma concentrations of itraconazole were reached within 3 to 5 days after initiation of treatment and maintained throughout treatment.</p><p><u>Hydroxypropyl-</u> &beta; <u>-Cyclodextrin</u></p><p>The oral bioavailability of hydroxypropyl-&beta;-cyclodextrin given as a solubilizer of itraconazole in oral solution is on average lower than 0.5% and is similar to that of hydroxypropyl-&beta;-</p><p>&nbsp;</p><p>&nbsp;</p><p>cyclodextrin alone. This low oral bioavailability of hydroxypropyl-&beta;-cyclodextrin is not modified by the presence of food and is similar after single and repeated administrations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Itraconazole</u></p><p>Acute oral toxicity studies with itraconazole in mice, rats, guinea-pigs and dogs indicate a wide safety margin (3- to 16-fold of Maximum Recommended Human Dose [MRHD] based on mg/m2).</p><p>Itraconazole is not a primary carcinogen in rats or mice up to 20 and 80 mg/kg, respectively. Nonclinical data on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itraconazole&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; revealed&nbsp;&nbsp; no&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indications&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gene&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; toxicity,&nbsp;&nbsp;&nbsp; primary carcinogenicity or impairment of fertility. At high doses, of 40 and 80 mg/kg/day in rats (1- and 2-fold of MRHD based on mg/m2), effects were observed in the adrenal cortex, liver and the mononuclear phagocyte system but appear to have a low relevance for the proposed clinical use. Itraconazole was found to cause a dose-related increase in maternal toxicity, embryotoxicity and teratogenicity in rats and mice at high doses. A global lower bone mineral density was observed in juvenile dogs after chronic itraconazole administration, (no toxicity was observed up to 20 mg/kg (2-fold of MRHD based on mg/m2), and in rats, a decreased bone plate activity, thinning of the zona compacta of the large bones, and an increased bone fragility was observed.</p><p><u>Hydroxypropyl-&beta;-cyclodextrin</u></p><p>Non-clinical data reveal no special hazard for humans based on conventional studies of repeated dose toxicity, genotoxicity, and toxicity to reproduction and development. In a rat carcinogenicity study (at 80 mg/kg dose (2-fold of MRHD based on mg/m2)), hydroxypropyl-&beta;- cyclodextrin produced adenocarcinomas in the large intestine and exocrine pancreatic adenocarcinomas. These findings were not observed in a similar mouse carcinogenicity study. The clinical relevance of the large intestine adenocarcinomas is low and the mechanism of exocrine pancreatic adenocarcinomas induction not considered relevant to humans.</p><p><u>Reproductive toxicology</u></p><p>Itraconazole was found to cause a dose-related increase in maternal toxicity, embryotoxicity, and teratogenicity in rats and mice at 40, 80 and 160 mg/kg (0.5-, 1- and 4-fold of MRHD based on mg/m2). In rats, the teratogenicity consisted of major skeletal defects; in mice, it consisted of</p><p>&nbsp;</p><p>&nbsp;</p><p>encephaloceles and macroglossia. No teratogenic effects were found in rabbits up to 80 mg/kg dose (4-fold of MRHD based on mg/m2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hydroxypropyl betadex (Kleptose HPB), Propylene glycol, Hydrochloric acid 37%, Non- crystallizing sorbitol solution 70% (SORBIDEX 71205), Saccharin sodium, ART Cherry flavor # 349, ART Cherry flavor # 842, Ascorbic acid and Sodium hydroxide (pellets, extra-pure).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
In-Use Shelf life
In-Use Shelf life Use within 30 days of first opening the bottle, then discard any remainder.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>150ml Amber colored glass bottle</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Amarox Industrial Company,
Aljameah Street, Malaz quarter, Riyadh 11441 Saudi Arabia
Tel: +966 11 477 2215
Manufacture:
Annora Pharma Private Limited, India

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jan. 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>